∠matriderm®

Flexible solutions for complex wound reconstruction

UK DISTRIBUTOR





Study Types



Systematic Review

A summary and critical assessment of published studies that address a particular clinical issue. An organized method of locating, assembling, and evaluating literature on a particular topic including a set of specific criteria. A systematic review is typically structured in a description of the findings in the research studies and may also include a quantitative pooling and evaluation of the data, a so called meta-analysis.

Meta-Analysis

A meta-analysis is a statistical analysis that combines and compares the results from different studies to the same issue.

Randomized Controlled Trial

A controlled clinical trial where patients are allocated randomly (by chance) to two or more groups (i.e. treatment vs. placebo or new treatment vs. standard treatment). This set up aims at reducing bias and a quantitative evaluation of treatment outcomes.

Cohort Study (Prospective Observational Study)

An observational clinical research study in which people who share a common characteristic like a certain condition or receive a particular treatment are followed over time and compared with a control group that does not share the characteristic or is not affected by the condition. Thereby, connections between the characteristic and outcome or disease can be analyzed.

Case-control Study

Observational study where researchers choose people with a particular outcome (the cases) and check their records to analyze causal attributes (i.e. risk factors). They evaluate the potential relationships of certain causal attributes with the outcomes.

Cross-sectional Study

Empirical analysis and comparison of a defined population at a single point in time or a time interval with simultaneous determination of exposure and outcome.

Case Reports and Series

An observational report on a series of patients with an outcome of interest without control group.

Ideas, Editorials, Opinions

Authored by experts regarding a specific clinical field or topic.

Animal Research Study

Study set ups using animal subjects. Often used to test a certain treatment before using it in clinical studies with human patients.

Test-tube Lab Research

In vitro experiments that are conducted in a controlled laboratory setting.

Animal Studies

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Lamme E. N.	1998	The Journal of Investigative Dermatology	Living skin substitutes: Survival and functions of fibroblasts seeded in a dermal substitute in experimental wounds	animal study 3D cell culture	3 pigs	Collagen-elastin matrix + STSG	STSG alone		In the woun labeled cell a macroph 31 (+/-0.9) whereas ini percentage between w wounds tre of seeded c wounds wa with the acc macrophag in an artifici pigs survive
Geyer S. H.	2014	Annals of Anatomy	High resolution episcopic microscopy (HREM): A useful technique for research in wound care	animal study 3D cell culture	2 pigs	MatriDerm® + STSG	native MatriDerm®, MatriDerm® populated with keratinocytes	one-step	This article evaluating N architectur populated v appearance split skin gri surgical pro MatriDerm ⁶
Wietbrock J. O.	2016	Tierärztliche Fakultät der Ludwigs-Maximilians-Universität München	Funktioneller Gewebeersatz bei komplexen Hautweichteildefekten mit einer hämodynamisch stimulierten und in vivo axial vaskularisierten Bindegewebslappenplastik	thesis/animal testing	30 rats (analyzed 21)	MatriDerm®	Integra®		This study a a free conn vascular ne artificial tiss and cell mig correlated vasculariza MatriDerm ⁶ progression the centrun after expan
De Vries H.	1994	Wound Repair Regen	Dermal regeneration in native non cross linked collagen sponges with different extracellular matrix molecules	animal study (porcine model)		reconstituted and native collagen matrices + STSG	collagen matrix coated with alpha-elastin; coated with fibronectin, coated with hyaluronic acid	one-step	No inflamm within 1 wee remained ir component with native aberrant ep by more fib wound com amount of f optimal der collagen bu
Schneider J.	2009	Burns	MatriDerm [®] versus Integra [®] : a comparative experimental study	animal - comparative study (rats)		MatriDerm [®]	Integra®	2-step	MatriDerm [®] procedure i Neonatal ra No differend of epidermi
Böttcher- Haberzeth S.	2011	Pediatr Surg Int	MatriDerm [®] 1mm versus Integra [®] Single Layer 1.3mm for one-step closure of full thickness skin defects: a comparative experimental study in rats	animal - controlled study	15 rats	MatriDerm [®]	Integra® single layer and neonatal rat epidermis only	one-step	In the Matri Integra® Sir approximat a mean thic Integra®-ba
Philandrianos C.	2012	Burns	Comparison of five dermal substitutes in full-thickness skin wound healing in a porcine model	animal - randomized controlled study	10 pigs	MatriDerm® (2mm)	Integra ^{(®}), ProDerm ^{(®}), Renoskin ^{(®}), and Hyalomatrix ^{(®})	2-step (Grafted after 21 days)	No difference of healing. I Hyalomatriz and dermis study: STSC time for Ma is not optim
Killat J.	2013	Int. J. Mol. Sci.	Cultivation of keratinocytes and fibroblasts in a three-dimensional bovine collagen-elastin matrix (MatriDerm®) and application for full thickness wound coverage in vivo	animal study 3D cell culture		MatriDerm [®] seeded with keratinocytes and fibroblasts		n.ap	Long-term Full matrix I Seeded Ma Integration difference b

omes/Summary

nds treated with the seeded dermal substitute, fluorescent PKH-26lls were detectable up to 6 d and were positive for vimentin but not for nage antibody. After 5 d, flow cytofluorometry showed the presence of) x 10 (6) (mean +/- SD, n = 7) PKH-26-positive cells in these wounds, nitially only 1 x 10 (6) fluorescent fibroblasts had been seeded. In total, the e of mesenchymal cells minus the macrophages was similar after 5 d wounds treated with the seeded and the acellular substitutes. In the eated with the seeded substitute, 19.5% of the mesenchymal cells were origin. Furthermore, the rate of substitute degradation in the seeded as significantly lower at 2-4 wk after wounding than in wounds treated bellular substitute. Vascular in-growth and the number of infiltrated ges were not different. In conclusion, cultured dermal fibroblasts seeded cial dermal substitute and transplanted onto full-thickness wounds in ed and proliferated.

e discusses the use of high-resolution episcopic microscopy (HREM) for MatriDerm® ex- and in vivo. HREM was able to visualize the exact fiber re of MatriDerm® and the distribution of keratinocytes in matrices with keratinocytes. In addition, HREM was used to visualize the be and revascularization of MatriDerm® after its implantation beneath rafts. The results suggest that HREM can be a useful tool for optimizing ocedures and post-implantation wound treatment regimes using ®

aimed to determine the optimal matrix and prefabrication duration for nective tissue flap based on an arteriovenous (AV) loop, which is a viable etwork that allows for sufficient oxygen supply and in vivo Integration of sue. The study found that MatriDerm® resulted in higher vessel formation igration than Integra® DRT, and that the use of a stiff, elastic matrix with increased in vivo vascularization and cell migration. Increased ation, increased cell migration into the matrix, degradation of ® after 4 weeks, higher vessel density, increased strong-elasticity (linear n for expansion untill 30%, n = 2), higher tear strength, cells were found in m and periphery of the matrix, complete restoration of the original length nsion of the matrix (compared with Integra®), less thrombosis.

natory responses were observed. Reconstituted matrices degraded ek, native matrices lasted 2 weeks, native matrices with additions intact for up to 4 weeks. Larger amounts of newly formed matrix its in native matrices with coatings. Best aesthetic results were obtained e collagen coated with elastin. Fibronectin-treated matrices caused pithelization. When hyaluronic acid was added, matrices were invaded problasts and myofibroblasts. This process correlated with fibrosis and ntraction. In contrast, the native collagen/elastin matrix reduced the fibroblasts #and myofibroblasts. Collagen-elastin matrix resulted in irmal regeneration, the formation of a neodermis with random organized undles and little wound contraction by dimished myofibroblast expression.

n® and the dermal part of Integra® were compared in a two-step including matrix implantation and subsequent epidermal grafting. at epidermis was used as coverage to test for rapid and complete take. nee in efficiency and quality of vascularization expressed by take rate his, and thickness of resulting neodermis.

iDerm[®] group, neodermal mean thickness of 0.49 mm (SD 0.03 mm). ngle Layer group mean thickness of 0.67 mm (SD 0.015 mm). Both ting the physiological dermal-epidermal ratio. In the control group, ckness of 0.27 mm (SD 0.036 mm). Cell density was higher than the ased neodermis. There were no difference in other parameters.

nce in wound contraction and in Vancouver scale after 2 and 6 months Integration of Integra® was significantly less than Integration of ix 1 (p = 0.022) and MatriDerm® 1 (p = 0.020). In all cases, the epidermis s was reconstructed with a papillary basal membrane. Limitations of G was placed 21 days after placement of MatriDerm®. Optimal grafting atriDerm® is 7-12 days post-op. 21 day grafting as shown in this study mal for MatriDerm®.

cell survival, migration and proliferation of keratinocytes and fibroblasts. Integration and wound healing and stable epithelialization at 3 weeks. atriDerm® sheets showed full Integration in the wound model. Excellent a concerning epithelial regeneration and stratification. No significant between the skin substitute and normal skin in the animal.

Animal Studies

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Michael S.	2013	PLOS	Tissue Engineered Skin Substitutes Created by Laser-Assisted Bioprinting Form Skin-Like Structures in the Dorsal Skin Fold Chamber in Mice	animal/in vitro Bioprinting		MatriDerm®			Via the use MatriDerm ⁴ growing into direction of epidermis v MatriDerm ⁴ harmful effe
Wiedner M.	2014	Wound Repair Regen	Simultaneous dermal matrix and autologous split-thickness skin graft transplantation in a porcine wound model: a three-dimensional histological analysis of revascularization	animal study		MatriDerm® + STSG	STSG alone	one-step	The study a application episcopic n dermal mat revasculariz dermal laye thickness o in the matri
Lee	2016	Materials Science and Engineering C	Three dimensional poly (ε-caprolactone) and silk fibroin nanocomposite fibrous matrix for artificial dermis	in vitro/ animals study		poly (ε-caprolactone) and silk fibroin nanocomposite fibrous matrix	MatriDerm® (in vivo model, histology)		The study n fibrous mat dermis app 15 days of ir 5 days post blood vesse filling of der
Leibig	2016	Plast. Reconstr. Surg.	Flow-Induced Axial Vascularization: The Arteriovenous Loop in Angiogenesis and	animal study			MatriDerm® (4mm) (2 layer 2mm)		Arterioveno connective after AV loo
Petersen	2016	Burns	The use of collagen-based matrices in the treatment of full-thickness wounds	animal Study	collagen- gelatin: n = 36, MatriDerm® (1mm) n = 6, untreated wounds = 6	Collagen-gelatin fleece (newly applied every second day), MatriDerm [®] one application	no treatment	no STSG, Wounds were covered by occlusive foil and Fixomull tape	The article of to untreated study found of MatriDen dermal wou achieved in applied mul average bein compared to collagen-ge 31, collagen cell count M wounds sho
Tuca	2016	Placenta	Comparison of Matrigel and MatriDerm® as a carrier for human amnion-derived mesenchymal stem cells in wound healing	animal study/ technical note	18 rats	1) MatriDerm® + AMSC (n=4) 2) MatriDerm® (n=5) vs MatriDerm® + AMSC (nv=5)	1) Matrigel + AMSC (n = 4)		The use of I cells (AMSC the wound a to MatriDer for AMSC a adequate p MatriDerm [®]
Schmidt	2017 a	Journal of Tissue Engineering and Regenerative Madicine	Hemodynamically stimulated and in vivo generated axially vascularized soft tissue free flaps for closure of complex defects: Evaluation in a small animal model	animal study/ prospektiv	35 female Sprague Dawley rats	group 2: AV loop flap produced by the use of MatriDerm® (2mm) + split thickness skin graft	group3: MatriDerm®(2mm) + split thickness skin graft group 1: split thickness skin graft	one-step	The article i the reconst found that t homogeneo was eviden mean vesse matrix were erated flaps compared t and is suita
Schmidt	2017 b	Ann Plast Surg	Collagen-Elastin and Collagen-Glycasamino- glycan Scaffolds Promote Distinct Patterns of Matrix Maturation and Axial Vascularization in Arteriovenous Loop-Based Soft Tissue Flaps	animal study	19 female Sprague Dawley rats	MatriDerm®	Integra®		The study e engineering Integra® ho but MatriDe network. Ma higher cell r
Ertl	2018	Placenta	Comparative study of regenerative effects of mesenchymal stem cells derived from placental amnion, chorion and umbilical cord on dermal wounds	in vitro/ animals study	mice (n = 5 per group)	MatriDerm® as carrier for mesenchymal stem cells	MatriDerm® alone		Three types effects on w significantly wound com further import all three PM neovascula

omes/Summary

 of LaBP, a multi-layered, fully cellularized skin equivalent was created.
becomes populated by the printed fibroblasts. Blood vessels started o MatriDerm[®] from the wound bed and the wound edge mostly in the f the transplanted cells. The printed keratinocytes formed a multi-layered with beginning differentiation and stratum corneum. The transplanted
skin construct Integrated well into the surrounding tissue and no ects occurred.

analyzed the revascularization process involved in the simultaneous of dermal matrices and split-thickness skin grafts using high-resolution microscopy in a porcine excisional wound model. The presence of the trix did not decelerate the revascularization process, and the zation process was comparable in both groups. The thickness of the er increased in both groups, revealing a statistically significant higher of the dermal matrix group vs. control on day 5 and day 28. New vessels ix are visible at day 10. MatriDerm[®] not visible anymore after 15 days.

eports a novel strategy to "engineer" a controlled 3D nanocomposite rix of poly (ε-caprolactone) (PCL) and silk fibroin (SF) for an artificial lication. MatriDerm® showed faster healing than the other scaffold, after mplantation wound size decreased noticeably. All specimens showed at t-implantation a foreign body reaction, 10 days post-implantation: new els formed. Better binding of MatriDerm® to host tissue but no complete mal defects.

ous loop with MatriDerm[®]-filled isolation chamber showed a e tissue nourished by the newly formed vascular network 4 weeks op placing.

examines the effect of a novel collagen-gelatin fleece in comparison ad controls and MatriDerm[®] in the healing of deep dermal wounds. The d that all tissue-engineered products, including the single application rm[®] and any concentration of the collagen-gelatin fleece, accelerated und healing compared to untreated wounds. The best outcomes were n wounds covered with 150 g/m² collagen-gelatin fleece, especially when ultiple times, as well as in wounds covered once with MatriDerm[®], with an enefit of 2.83 days. Skin quality also improved in both template groups to untreated controls. Wound closure with MatriDerm[®]: 10,67 days, with elatin 11 days. Epidermal thickness after 21 days: MatriDerm[®]: n-gelatin single application: 27,74, multiple application 30,8, Epidermal MatriDerm[®]: 84,5 cells, collagen-gelatin: 52/54 cells. Only MatriDerm[®]

MatriDerm® in combination with amnion-derived mesenchymal stem C) has shown promising outcomes in promoting neovascularization of area and enhancing wound closure and capillary formation compared rm®-only treated wounds. While Matrigel proved to be an excellent matrix and immigrating mouse cells, the solid MatriDerm® enabled a more positioning of AMSC into the wound. Although AMSC did not attach to ®, they reliably induced wound reduction.

reports on a study that evaluated the use of AV-loop-generated flaps for truction of critical bone-exposing defects using a rat model. The study the AV-loop-generated flaps resulted in stable wound coverage with ous vascular Integration compared to the control groups. Neoangiogenesis at in all constructs, and significant increases in mean vessel number and el area were observed over time. Cell migration and proliferation into the e also observed, with a significant increase over time. The AV-loop-gens resulted in sufficient defect reconstruction and stable tissue coverage to the control groups. MatriDerm[®] efficiently promotes neovascularization able for tissue engineering of vascularized soft tissue flaps.

evaluated different collagen-based scaffolds for soft tissue g using an arteriovenous (AV) loop model in rats. Both MatriDerm® and wed increased vessel count and area at day 28 compared to day 14, erm® had a higher vessel count and more homogeneous vascular atriDerm® showed better vascularization compared to Integra® and migration for MatriDerm®.

Three types of PMSCs (AMSCs, BV-MSCs, and WJ-MSCs) were evaluated for their effects on wound healing in mice using MatriDerm® as a carrier. All PMSC types significantly induced faster healing and a higher number of blood vessels in the wound compared to controls. Co-application with placental endothelial cells did not further improve the advantageous effects of PMSC treatment. Results indicate that all three PMSC types exert similar beneficial effects on wound closure and neovascularization in the mouse model. Using MatriDerm® as a carrier for PMSCs allows for a fast and clinically practicable method for stem cell application.

Animal Studies

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Gasanz	2018	Cent European J Urol	Use of an acellular collagen-elastin matrix to support bladder regeneration in a porcine model of peritoneo cystoplasty	animal Study	n=11/n=5	peritoneum graft + MatriDerm® (1mm)	Peritoneum graft	one-step	In a study u matrix in bla matrix shov genesis and differences while the us consider it a
Hatzfeld	2019	IWJ	Benefits of cryoerserverd human amnotic mambranes in association with conventional treatments in the manaement of full-thickness burns	animal study + clinical cas Report		MatriDerm® + STSG and MatriDerm® + STSG + HAM	STSA alone and STSA plus human amniotic membrane (HAM)	one-step	The addition autografts (contraction The presen- recruitment cells. In a cli retraction a palmar regi
Gonzalez- Quevedo	2020	THE BONE & JOINT JOURNAL	Improving the regenerative microenvironment during tendon healing by using nanostructured fibrin/agarose-based hydrogels in a rate Achilles tendon injury model	animal		MatriDerm [®]	nanostructured fibrinagarose hydrogel (NFAH) or genipin cross-linked nanostructured fibrinagarose hydrogel (GP-NFAH)		The study ir tendon hea significantly repaired ter organization histological
Maitz	2020	J Tissue Eng Regen Med.	The effects of cross-linking a collagen-elastin dermal template on scaffold bio-stability and degradation	in vitro/ animals study		MatriDerm®	MatriDerm® cross-linked		Cross-linkir significantly Furthermor after 14 day with a simila MatriDerm [®] promote the
Eisler	2022	Applied Sciences	Assessment of two commonly used dermal regeneration templates in a swine model without skin grafting	animal study	18 full thickness wounds pig	MatriDerm® (1mm) without STSG	Integra® without STSG and control without dermal template	n.ap	The study of Integra® - o both MatriD wound clos Integra® at MatriDerm [®] Rete ridge f groups. Ove

In-vitro studies

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Welling O.	2008	Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg im Breisgau	Hautersatz durch Kultivierung von humanen Keratinozyten und Fibroblasten in einer Kollagen-Elastin Matrix in vitro und in vivo im Nacktmausmodell	in vitro/in vivo (thesis) 3D cell culture	48 mice			one-step	Matriderm® and stability full-thickness full-thickness no purulenc closure at da populated w migration int at day 14, fib detection ur
Golinski	2011	Journal of Periodontal Research	Oral mucosa model based on a collagen-elastin matrix	in vitro		MatriDerm®			Histological, dermal/epic hemidesmo the epiderm experiments with dindival

omes/Summary

using a porcine model, the benefits of using an acellular collagen-elastin adder augmentation were examined. After 6 weeks, the group with the wed less retraction and better histological results (including neo-angiod less fibrosis) compared to the group without the matrix. However, no s were observed in functional test results and the study concluded that se of the matrix was beneficial, further improvements are needed to an appropriate cystoplasty technique.

In of cryopreserved amniotic membranes (HAM) to split-thickness skin (STSA) or STSA with the dermal substitute MatriDerm® reduced scar in and increased scar elasticity in an experimental model for deep burns. Ince of HAM increased dermal neovascularization and fibroblast it to the wound site, but had no effect on the recruitment of inflammatory linical case study, the use of HAM with MatriDerm® reduced dorsal and allowed for good elasticity on the dorsal skin of the hand, while the ion without HAM had high rigidity with strong retraction.

investigated the effect of MatriDerm®, NFAH and GP-NFAH on Achilles aling in rats. The results showed that NFAH and GP-NFAH had ly higher tensile strength compared to MatriDerm®. In vivo evaluation of endons using NFAH, GP-NFAH and MatriDerm® resulted in better on of collagen fibers and cell alignment than direct repair, with a better al score in GP-NFAH.

ng MatriDerm[®] resulted in a threefold increase in tensile strength, ly less protein loss, and reduced scaffold contraction in vitro. re, non-cross-linked MatriDerm[®] was almost completely biodegraded ys in a mouse model, whereas cross-linked MatriDerm[®] remained intact lar host response. The extended structural integrity of cross-linked l[®] could potentially facilitate improved skin tissue regeneration and he formation of a more pliable scar.

The study compared the effectiveness of two dermal substitutes – MatriDerm® and Integra® – on full-thickness skin defects without a STSG. The results showed that both MatriDerm® and Integra® treatment groups demonstrated significantly faster wound closure than the control group, with MatriDerm® at 10.67 +/- 0.94 days and Integra® at 10.00 days +/- 1.15 days. The histologic examination revealed that MatriDerm® had lower epidermal thickness than Integra® tout a higher cell density. Rete ridge formation was visible for both MatriDerm® and Integra® treatment groups. Overall, the study showed that MatriDerm® and had an improved wound healing and resulted in faster re-epithelialization compared to the control group when used without STSG.

mes/Summary

¹ is very stable under cell culture conditions (no changes in structure *y*), good population on Matriderm[®] with keratinocytes and fibroblasts, as skin substitution: better wound healing with Matriderm[®] compared to as wound without substitution (faster wound closure and epithelization, be), best results for groups for Matriderm[®] populated with cells: wound lay 7, decreased contracture, mature epithelium for Matriderm[®] with cells at day 14, closed multilayered epithelium at day 28, high to the matrix, vascularization visible at day 14, basement membrane problasts only in close proximity to keratinocytes (at day 28 increased nder basement membrane).

Histological, immunohistochemical and electron microscopic analysis of the dermal/epidermal junction showed a typical basement membrane and hemidesmosomal structures. Neighboring keratinocytes formed desmosomes in the epidermal sections. Cytokeratin was detectable in all epidermal layers. These experiments revealed that the collagen-elastin matrix was highly biocompatible with gingival cells under ex vivo conditions.

In-vitro studies

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Zöller N.	2014	Dermatology	Clinical application of a tissue-cultured skin autograft: An alternative for the treatment of non-healing or slowly healing wounds?	in vitro/clinical	1 case	MatriDerm® + tissue-cultured skin autograft			The study s treatment for surface. Aur and seeded transplante structure at undisturbed
Golinski	2009	Handchir Microchir Plast Chir	Development of an engraftable skin equivalent based on MatriDerm® with human keratinocytes and fibroblasts	in vitro		MatriDerm®			Histological Observed oc and dermis oytokeratin microscopie zone as wel differentiatie found in the that a skin e an expansio
Lee	2016	Materials Science and Engineering C	Three dimensional poly (ε-caprolactone) and silk fibroin nanocomposite fibrous matrix for artificial dermis	in vitro/ animals study		poly (ε-caprolactone) and silk fibroin nanocomposite fibrous matrix	MatriDerm®		The study n fibrous mat dermis app 15 days of ir 5 days post new blood complete fil
Alharbi	2023	Med Sci (Basel)	The LipoDerm Method for Regeneration and Reconstruction in Plastic Surgery: A Technical Experimental Ex Vivo Note	experimental ex vivo					In an ex vive Matriderm [®] layer of the structure or used as a b regeneratio aesthetic or
Mulder	2023	J Funct Biomater	Full Skin Equivalent Models for Simulation of Burn Wound Healing, Exploring Skin Regeneration and Cytokine Response	ex Vivo	n.ap	MatriDerm [®]	Mucomaix	n.ap	In an in vitro (FSEs) show vivo human positive epid stratum con the MatriDe based FSEs proliferating regenerate in all FSE m observed of MatriDerm [®] facilitate res
Monsuur	2018	J Cell Physiol	Endothelial cells enhance adipose mesenchymal stromal cell-mediated matrix contraction via ALK receptors and reduced follistatin: Potential role of endothelial cells in skin fibrosis	in vitro		MatriDerm® for the generation of in vitro fibrosis model			MatriDerm [®] between en mesenchyn (EC) could s mediated m scars, via re in this proce follistatin de
Dill	2020	IWJ	Biological dermal templates with native collagen scaffolds provide guiding ridges for invading cells and may promote structured dermal wound healing	in vitro		MatriDerm®	Integra® Pelnac		The study ir biological d Matriderm [®] viability con In contrast, showed a le suggest tha networks, s wound heal

omes/Summary

suggests that tissue-cultured skin autografts may be an alternative for full-thickness wounds and wounds that cover large areas of the body tologous epidermal and dermal cells were isolated, expanded in vitro d on MatriDerm[®] scaffolds, resulting in a skin equivalent that was ed onto a facial chronic ulceration of a 71-year-old patient. The skin t the transplantation site closely correlated with the adjacent d skin after 138 days, indicating the potential for clinical applications.

I analysis showed a regularly stratification of the epidermal part. collagen IV, a marker for the basement membrane, between epidermis s. Desmoglein and the differentiation markers involucrine and n 10 were found in the suprabasal layers of the epidermis. Electron ic analysis showed the basement membrane in the epidermal junction ell as cell-cell connections in the form of desmosomes. Late ion characteristics, like granular structures and the cornified layer, were e stratum granulosum and stratum corneum. Results demonstrate equivalent can be generated by using a collagen/elastin matrix, with on rate of 50-100-fold.

eports a novel strategy to "engineer" a controlled 3D nanocomposite rix of poly (ε-caprolactone) (PCL) and silk fibroin (SF) for an artificial lication. MatriDerm® showed faster healing than other scaffold, after mplantation wound size decreased noticeably. All specimens showed at t-implantation a foreign body reaction, 10 days post-implantation: vessels formed. Better binding of MatriDerm® to host tissue but no lling of dermal defects.

o experimental note, nanofat-containing ASCs were seeded onto for cellular enrichment and found to be viable and attached to the top scaffold within 1 hour of incubation. The proposed multi-layered ontaining nanofat and dermal template (Lipoderm) could potentially be piological regenerative graft for wound defect reconstruction and on in a single operation, leading to more optimal regeneration and utcomes.

o study on skin regeneration, MatriDerm[®]-based full skin equivalents wed proper dermal and epidermal morphogenesis, comparable to ex a skin models, with a well-developed dermis and pan-cytokeratinidermis, including a basement membrane, stratum spinosum, and rneum. After a standardized burn injury, re-epithelization occurred in erm[®]-based FSEs at 2 weeks, similar to ex vivo human skin. MatriDerm[®]s showed regenerative capacity with a neo-epidermis that contained g cells, whereas FSEs based on Mucomaix were not observed to the burned epidermis. The level of pro-inflammatory cytokines was high nodels, including MCP-1, IL-4, IL-6, and IL-8, with a modest increase only in MatriDerm[®]-based FSEs in response to burn injury. [®]-based FSEs can serve as a preclinical animal-free in vitro model to research on skin.

[®] was used to develop an in vitro fibrosis model to study the interaction ndothelial cells (EC) and dermal fibroblasts or adipose tissue-derived mal stromal cells (ASC). This in vitro study found that endothelial cells stimulate adipose tissue-derived mesenchymal stromal cells (ASC)natrix contraction, leading to a fibrotic phenotype, similar to hypertrophic egulation of fibrosis-related proteins. The TGF-β pathway played a role less, and inhibiting the ALK4/5/7 receptors or adding recombinant ecreased matrix contraction.

nvestigated the ultrastructural features and properties of different lermal templates, specifically focusing on the impact of collagen nativity. [®] demonstrated enhanced cell adherence, spreading, proliferation, and mpared to Integra[®] and Pelnac, likely due to its intact collagen network. , biomaterials with lesser amounts of native collagen fibril networks ess pronounced potential to harbor these properties. The results at biological dermal templates with higher content of native collagen such as Matriderm[®], may be beneficial for promoting accelerated ling and tissue regeneration.

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
van Zuijlen P. P. M	2001	Plastic and Reconstructive Surgery	Dermal substitution in acute burns and reconstructive surgery: A subjective and objective long-term follow-up	prospective, intra-individual	31	MatriDerm [®] + meshed split skin graft (wounds treated with silver sulfadiazine. Paraffin gauze and absorbent cotton soaked in a polyethylene/glycol/ sorbitol povidone- iodine solution were applied on the top of the graft)	split skin graft (wounds treated with silver sulfadiazine. Paraffin gauze and absorbent cotton soaked in a polyethylene/glycol/ sorbitol povidone- iodine solution were applied on the top of the graft)	one-step	Higher elas significanco Most patier substitute s grafts. The control site Cutometer statistically substituted
Ryssel H.	2008	Burns	The use of MatriDerm [®] in early excision and simultaneous autologous skin grafting in burnsa pilot study	prospective controlled	10	MatriDerm® + STSG	split thickness skin graft	one-step	MatriDerm ¹ pliability (V score STSC survival bet
Dantzer E.	2009	Journal of Wound Technology	MatriDerm®: a new single-layer regeneration transcript	case series, retrospective analysis	15	MatriDerm®	none	one-step	In patients degrees the alone. No fa substitute of tissue appli compared results are period of 8
Lumenta D.	2009	J Burn Care Res	Adult burn patients with more than 60% TBSA involved-Meek and other techniques to overcome restricted skin harvest availabilitythe Viennese Concept	comparative cohort	17	Meek, MatriDerm® as concomitant treatment	Non Meek, MatriDerm® as concomitant treatment		MatriDerm ⁱ importance stay or nun burn patier
Ottomann C.	2009	Zeitschrift für Wundheilung	Die Kombination dermalen Ersatzes (MatriDerm®) und V.A.C. [article in German]	case series, retrospective analysis	105	MatriDerm®	none	one-step	93% unco
Bloemen M.	2010	Plast Reconstr Surg	Dermal substitution in acute burns and reconstructive surgery: a 12-year follow-up	prospective controlled	46	MatriDerm® + STSG	STSG alone	one-step	Even after 1 reconstruc seen betwe elasticity p statistically seen in sur (better) in s burn group scars in all observer so lower (better
Bloemen M.	2012	Wound Repair Regen	Clinical effectiveness of dermal substitution in burns by topical negative pressure: a multicenter randomized controlled trial	randomized controlled trial	86	STSG + MatriDerm® with or without TNP	STSG without MatriDerm® and with or without TNP	one-step	No significa 96.1%). Sig postoperat group. At 12 treated with significant of TNP: 3.2; M MatriDerm
Нор М.	2013	Burns	Cost study of dermal substitutes and topical negative pressure in the surgical treatment of burns	randomized controlled trial	86	STSG + MatriDerm [®] with or without TNP	STSG with or without MatriDerm® and with or without TNP	one-step	12 month p MatriDerm with MatriD stay was re (2 ICU days STSG group groups (rar
Shin J. U	2014	International Journal of Dermatology	Extramarginal excision is preferable for hypertrophic scars	randomized controlled trial	15	7 children treated with AlloDerm® or MatriDerm® + STSG (2 patients intramarginal excision, 4 patients extramarginal excision. 1 patient both) (unspecified)	8 children treated with FTSG (4 patients intramarginal excision, 4 patients extramarginal excision)	not reported	Study evalu hypertroph intramargir extramargi followed by hypertroph related to r patients ree
Bonnet A.	2015	Ann Chir Plast Esthet (Annales de chirugie plastique esthetique)	Operating room fire: should we mistrust alcoholic antiseptics	retrospective	4	MatriDerm [®] + skin graft (partially, 1 patient)	skin graft (3 patients)	one-step	34 yr old w with a seco

omes/Summary

sticity data reported for area with MatriDerm®, but without statistic be. Measurements for burn wounds were comparable with control group. Ints gave higher ratings for the substituted site. Effectiveness of dermal seemed to have a relation with the expansion rate of the overlying mesh substituted site seems smoother and more supple compared with the es when large expansion rates of the graft were applied. For these cases r measurements were higher, skin extension and pliability showed a y significant difference. Patients impression was higher for the d site.

 $^{\odot}$ significantly improved scar elasticity. Significant improvement of /BSS score) for sheet autografts. VBSS score MatriDerm $^{\odot}$ = 3, VBSS G = 6 (p = 0.04)T ake rate: 83,4% (p = 0.25). No difference in graft stwen MatriDerm $^{\odot}$ and STSG alone groups.

treated for loss of substance presenting vascular deficiencies of various the MatriDerm® take was longer than using a split thickness skin graft ailures were observed. Scars were pliable and elastic. In general, dermal does not decrease complete healing-time but the quality of the final lied to be better, especially over bone structure. Adherences is minimized to split skin grafts applied over the same anatomical area. Functional good. A return to a normal color was observed in one patient after a 8 months. No Scar retractions.

I® served as a dermal template for coverage of areas of functional e. Meek group vs non-Meek group had no difference in LoS, hopsital mber of operations. Meek technique is a treatment option in severe nts.

mplicated success rate.

12 years an improved scar parameters was found in both acute and btive substituted wounds. In the acute burn group, no differences were een substituted and reference scars. In the reconstructive scars, all varameters were higher in substituted scars. In the acute burn group, no y significant difference between substituted and reference scars was rface roughness. However, the three roughness parameters were lower substituted scars. Subjective scar assessment (POSAS) in the acute o showed a statistically significant difference in favor of the substituted items, except for vascularization. In the reconstructive group, cores for pliability, relief, and the general score also showed significantly ter) results for substituted scars.

ant difference in graft take and epithelialization (ranging from 92.4% to gnificantly fewer wounds in the TNP alone group showed tive contamination. Significant better elasticity in MatriDerm® + TNP 2 months postoperatively, surface roughness scores were lower in scars th MatriDerm® (indicating a smoother surface), however without differences. Patient POSAS score at 12 months: MatriDerm® + STSG + MatriDerm® + STSG: 3.7; TNP: 2.9; STSG alone: 3.4 Surgeon POSAS score: 1[®] + STSG+TNP: 2.7; MatriDerm® + STSG: 3.2; TNP: 2.6; STSG aline: 2.8.

post-op: highest elasticity was measured in scars treated with [®] and TNP (ratio Uf 0.80, p = 0.027). The initial cost price of treatment Derm[®] and TNP was €2912 (p < 0.001). The mean length of hospital espectively 21 days (including 1 ICU day), 24 days (3 ICU days), 22 day s), 21 days (1 ICU day) in the MatriDerm[®]-TNP, MatriDerm[®], TNP, and Ip. Mean total costs per patient did not differ significantly between nge €29097 - €43774).

uated the influence of surgical margins on the recurrence of nic scars and keloids and compared the recurrence rates between nal excision and extramarginal excision. The study found that inal excision with complete removal of the abnormal collagen bundles y skin grafting is a viable alternative to reconstruction of the foot after nic scar excision, and this treatment can effectively decrease issues recurrence. All grafts survived, no wound dehiscence. None of the exceived postoperative adjuvant therapy.

vith 3 rd degree burn on the thigh and hip. MatriDerm® + STSG placement ond graft at day 39. Wounds fully healed at day 48.

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Demircan M.	2015	Burns	Preliminary results in single-step wound closure procedure of full-thickness facial burns in children using the collagen-elastin matrix and review of pediatric facial burns	case series	15	MatriDerm® + unmeshed split thickness skin	none	one-step	Improved co All grafts tra was close to color. Esthe
van Zuijlen	2000	Plast Reconstr Surg	Graft survival and effectiveness of dermal substitution in burns and reconstructive surgery in a one-stage grafting model.	prospective intra-individual controlled study	62	MatriDerm® + STSG	STSG alone	one-step	MatriDerm [®] and compa did not alter after recons 31 (44 scars elasticity pa pliability, ela in one-stage reducing sc
van Zuijlen	2002	Burns	Long-term results of a clinical trial on dermal substitution. A light microscopy and Fourier analysis based evaluation.	prospective intra-individual controlled study	57	MatriDerm® + STSG	STSG alone	one-step	This clinical with an auto 28 biopsies membrane cells, vessel in collagen b
Haslik W.	2007	Burns	First experiences with the collagen-elastin matrix MatriDerm [®] as a dermal substitute in severe burn injuries of the hand	case series	10	MatriDerm [®] + STSG		one-step	Take rate: 9 achieved. O 14 days.
Atherton D.	2010	Plast Reconstr Surg	Early Excision and Application of MatriDerm® with simultaneous autologous skin grafting in facial burns	case report	1	MatriDerm [®] + STSG		one-step	MatriDerm [®] with cadave texture and
Haslik W.	2010	J Plast Reconstr Aesthet Surg	Management of full-thickness skin defects in the hand and wrist region: first long-term experiences with the dermal matrix MatriDerm®.	case series	17	MatriDerm® + STSG		one-step	Take rate: 9 of 15.6 in pa The overall 12 month Va
Martínez- Méndez J.	2010	Cir. plást. iberolatinoam	Terapia de vacío como adyuvante para el uso de sustitutos dérmicos monocapa (Combined use of vacuum assisted device and dermal monolayer substitutes)	randomized controlled trial	20	MatriDerm® + VAC	MatriDerm® without VAC	one-step	No statistica Significant o VAC group a rate of 85%
Ryssel H.	2010	Burns	Dermal substitution with MatriDerm® in burns on the dorsum of the hand	prospective controlled	18	MatriDerm® + STSG	STSG alone	one-step	The study for 96.8%±8.7 difference b need for re- with the der in both grou Matriderm® group (med motion mea Matriderm® Crease-Dist (p > 0.05).
Haik J.	2012	J Drugs Dermatol	Reconstruction of full-thickness defects with bovine-derived collagen/elastin matrix: a series of challenging cases and the first reported post-burn facial reconstruction	case series	7	MatriDerm® + STSG		one-step	Overall graf normal skin cushioning o
Seo DK.	2014	ASTR	Management of neck contractures by single-stage dermal substitutes and skin grafting in extensive burn patients	retrospective case series	28	MatriDerm®	AlloDerm®	one-step	MatriDerm [®] split-thickne The overall 27 out of 28 failed to affe dermis who Take rate 98 VSS 1 yr: 2.4 and good in
Delli Santi	2016	American Burn Association (Letter to the editor)	The Use of Dermal Regeneration Template (Matriderm® 1mm) for Reconstruction of a Large Full-Thickness Scalp and Calvaria Exposure	case	1	MatriDerm® (1mm)		one-step	MatriDerm [®] scalp burn i provided a l a rapid solu a higher qua non-collabo or meshed

omes/Summary

osmetic and functional skin quality compared to alternative techniques. ansplanted to the face survived. Average VSS 2,55 + / - 1,42. Graft quality o normal skin in terms of vascularity, elasticity, pliability, texture and tic and functional results have been encouraging.

⁹ was applied in a one-step procedure with a split-thickness autograft, ired to ta split-thickness autograft. The study showed that MatriDerm[®] r autograft survival but significantly improved skin elasticity and pliability structive surgery. Burn group: 31 (84 wounds). Reconstr. Group: s). Burns: 73.5% take rate (p = 0.015); no significant difference in arameters. Reconstr: 80.8% take rate (ns) and significant better asticity, skin extension and retraction. It is feasible to use MatriDerm[®] e grafting, and it can provide benefits in improving skin elasticity and aarring.

I trial compared conventional treatment to MatriDerm® in combination ograft for wound healing. Burn group: 29 biopsies. Reconstr. Group: b. No significant differences found for epidermal thickness, basement maturation, rete ridge ratio, fibroblasts, myofibroblasts, inflammatory ls, ECM maturation. No difference in collagen orientation. Difference bundles observed.

07%. No unstable scars or blisters observed. Full range of motion overall VSS: 3.2 +- 1.2. Excellent pliability. Start of physical therpay within

[®] was used to resurface facial and neck defects after initial procedure eric skin. Better than expected outcome with respect to facial contour, I expression. Including case photo's.

96%. No unstable scars or blisters observed. 12 month DASH score titients with burn trauma and 27.2 in patients with a radial forearm flap. score was 18.1, indicating that hand function was well re-established. ancouver scar scale is 1.7.

al difference in complication rate with a total complication rate of 20%. difference in take rate time: was $21,4\pm9$ days in the MatriDerm® without and $13,9\pm4$ days in the MatriDerm® with VAC group. Skin graft uptake 6.

ound that the take-rate for wounds treated with Matriderm® 1 was 73, while the control group had a take-rate of 94.6% ± 10.25. The between the two groups was not statistically significant (p > 0.05). The -grafting was also not significantly different between the group treated rmal substitute and the conventionally treated group, with a rate of 5.6% ups. However, the VBSS demonstrated a significant improvement in the 9 1 group (median 2, minimum 1, maximum 5) compared to the control lian 6, minimum 4, maximum 7) with a p-value of 0.02. The range of asured by Finger-Nail-Table-Distance was significantly better in the 9 1 group with a p-value of 0.04. On the other hand, Finger-Tip-Palmartance values did not differ significantly between the two groups

t take was excellent without complications. Graft quality was close to n in terms of elasticity, pliability, texture, and color. Good contour and of defects in weight bearing areas was also achieved.

[®] or AlloDerm[®] was used as a dermal substitute in combination with ess skin grafting to treat neck contracture in extensive burn patients. take rate was 95.9%, and excellent/good outcomes were shown in 8 patients. Complications occurred in 11 out of 28 patients, but no grafts ect recontracture except in one patient with a partial loss of artificial o underwent a follow-up skin graft without any problems. MatriDerm[®] 8.1% (p = 0.058) and VSS 1 yr: 2.23 (ns). AlloDerm[®] Take rate 93.9% and 47. Functional and aesthetic outcomes were excellent in 18 patients o nine patients.

MatriDerm[®] was used in a single procedure to reconstruct a large full-thickness scalp burn in a 43-year-old man, resulting from a suicide attempt. The prosthesis provided a better final aesthetic quality and simplicity of technique, allowing for a rapid solution and reducing recovery time. The use of Matriderm[®] also enables a higher quality of skin graft with less risk of infection, even in the case of patient non-collaboration. The product can be grafted immediately with autologous whole or meshed skin grafts, with an engraftment index equal to the autologous skin graft without the dermal prosthesis.

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Demircan	2017	J Turgut Ozal Med Cent	One-Step Reconstruction of Severe Burn Injury on the Face of A Child by Using the Collagen-Elastin-Matrix	case report	1	MatriDerm®		one-step	The use of I reconstruct quality graft hypertrophi outcomes. I healing.
Kamolz L.	2017	Handchir Mikrochir Plast Chir	Sekundäre Korrektur einer großflächigen Verbrennungsnarbe im Bereich des Handrückens mit einem Collagen-Elastin- Dermisersatz und Spalthaut	case study	1	MatriDerm®		one-step	20-year-old (VSS: 3 poir 8,3). The ca a later stag chiropractio
Yagmur	2017	Turkish Journal of Plastic Surgery	Post-Burn Skin Deformities of the Face and Neck Region in Pediatric Patients: Single-Stage Treatment Using Collagen Elastin Matrix	case serie	8	MatriDerm®		one-step	The use of I in a study w modalities v MatriDerm [®] surface are and patient complication postoperativ preoperativ average pat all complain
Hatzfeld	2019	IWJ	Benefits of cryoerserverd human amnotic mambranes in association with conventional treatments in the manaement of full-thickness burns	animal study + clinical cas report		MatriDerm® + STSG and MatriDerm® + STSG + HAM	STSA alone and STSA plus human amniotic membrane (HAM)	one-step	The addition autografts (contraction The presen- recruitment inflammato reduced do hand, while
Jackson	2019	J Burn Care Res	Matriderm® and split-skin grafting for full-thickness paediatric facial burns	case report	n=1	MatriDerm® (1mm)		one-step	The use of I girl with 60 great aesth resulted in r aesthetic o
Phillips	2020	Annals of burns and fire disasters	The use of dermal regeneration templates for primary bruns surgery in a UUK regional bruns centre	retrosprective case series	94	MatriDerm® (n = 59)	Integra® DRT (n = 35)	one-step for Matriderm®	Integra®-tre while for Ma 84% +/- 3 seen in 3 ou patients. Siz compared f observed in Matriderm® hypertrophi groups. Pat DRT treated heal. Further of all burnt a
Zajíček	2020	Acta Chir.Plast	DERMAL REPLACEMENT WITH MATRIDERM® - FIRST EXPERIENCE AT THE PRAGUE BURN CENTRE	case series	10	MatriDerm® + STSG			Matriderm [®] healing time infectious c
Karakol	2021	J Plastic Surgery and Hand Surgery	Recent strategic approach in postburn extremity scars and contractures	case series	29	Matriderm [®] + STSG + stem cell, fat and PRP injection		one-step	There were motion, with postoperati significant of between pr from 6.55 ± pigmentatio 3.62 ± 0.30 to 3.55 ± v

Matriderm[®], a collagen-elastin matrix, in severe post-burn facial action has resulted in 100% graft survival and early results show good ft with normal skin characteristics. Contour was achieved and no nic scarring occurred, leading to encouraging aesthetic and functional Matriderm[®] can be a useful adjunct in facial reconstruction for quick

d woman. 2 years post transplatation scar quality of the hands was good ints) and an excellent hand functionality was achieved (DASH Score: ase presented here shows that very good results can also be achieved at ge if consistent interdisciplinary follow-up care is followed after adequate c care.

MatriDerm® in pediatric patients with burn deformities was evaluated where eight patients were treated previously with non-surgical without any significant benefits. The study showed that the use of [®] eliminated all contractures and significantly reduced the average ea of defects postoperatively. The average contraction rate was 9.6%, it satisfaction was high. Additionally, there were no significant ons associated with graft take. The average VSS score at the 12th tive month (3.6 ± 0.91) was significantly (p < 0.05) lower than the ve score ((10.25 ± 1.38) , indicating a significant reduction in scarring. The atient satisfaction rate was 1.9, indicating good satisfaction Furthermore, ints such as itching and unsightly scars were resolved postoperatively.

on of cryopreserved amniotic membranes (HAM) to split-thickness skin (STSA) or STSA with the dermal substitute Matriderm® reduced scar in and increased scar elasticity in an experimental model for deep burns. Noe of HAM increased dermal neovascularization and fibroblast it to the wound site, but had no effect on the recruitment of ory cells. In a clinical case study, the use of HAM with Matriderm® orsal retraction and allowed for good elasticity on the dorsal skin of the e the palmar region without HAM had high rigidity with strong retraction.

MatriDerm[®] acellular dermal matrix with split-skin grafts in a 3-year-old % full-thickness facial burns resulted in a 95% graft take on day 5 and netic outcomes in texture and color after 12 months. The technique also normal ocular and near-normal oral function, showing promise for both butcome and functional skin movement in burn reconstruction.

eated patients had an average percentage TBSA burn of 20.4% +/- 18.9, latriderm®-treated patients it was 1.7% +/- 1.3. The graft take rate was 33.3 for Matriderm® and 72.9% +/- 39.1 for Integra®. Major infections were but of 59 Matriderm®-treated patients and 11 out of 35 Integra®-treated ix patients in the Integra® group experienced complete loss of autograft to two patients in the Matriderm® group. Burn contractures were n 21 patients treated with Integra® and 15 patients treated with ®. There was no significant difference in haematoma development, nic scarring, or the need for secondary reconstructive surgery in both tients treated with Integra® had a mean time of 44.1 days to healing of the ed area, comparedto Matriderm®-treated patients, who took 20.1 days to ermore, Integra®-treated patients took longer to achieve a 95% healing : areas than Matriderm®-treated patients (66 days vs. 40.2 days).

[®] was used in the treatment of skin loss in ten patients. The average e was 19.6 days, with good functional results and without serious complications.

e statistically significant improvements in postoperative range of th a mean preoperative score of 36.14 ± 5.91 increasing to 74.31 ± 6.96 tively, representing a significant increase (p < 0.05). There were also decreases in all Patient and Observer Scars Evaluation Scale factors preoperative and postoperative scores, with mean scores decreasing ± 0.20 to 3.93 ± 0.24 for vascularity, from 6.62 ± 0.21 to 3.66 ± 0.23 for ion, from $6.55 \pm v0.21$ to 3.55 ± 0.23 for thickness, from 6.72 ± 0.22 to 0 for relief, from 7.17 ± 0.23 to 3.34 ± 0.24 for pliability, and from 6.72 ± 0.21 0.24 for surface area, respectively (p < 0.05 for all factors).

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Correa	2022	Wound Rep Regener	Evaluation of contraction of the split-thickness skin graft using three dermal matrices in the treatment of burn contractures: A randomised clinical trial	RCT	39	MatriDerm® (n = 9)	Pelnac (n = 10), Integra® (n = 10) no dermal template (n = 10)	one-step	A clinical tri- contracture groups trea only skin gra graft contra contraction and Matride not reduce
Park	2022	Journal of Korean Burn Society	The Treatment of Chronic Postburn Scar and Contracture: A Case Report	case report	1	MatriDerm® + STSG	none	one-step	This case st scarring in a had limited involved ren substitute, N The skin gra satisfaction using Matril
Young Lee	2022	Analyt Cellular Pathol	Immunohistochemical analysis of post burn scars following treatment using dermal substitutes	comparative clinical study		MatriDerm® + STSG (n=11)	AlloDerm® + STSG (n = 18), FTSG alone (n = 6), STSG alone (n = 28), normal skin (n = 63)		Based on the racteristics III, stromal C and laminin numbers co pared to FT lower levels MatriDerm® cantly higher may be an o posed by ot
Dickson	2023	J Burn Care Res	A Histological and Clinical Study of MatriDerm [®] use in Burn Reconstruction	case series	8	Matriderm®		one-step	A study was and an imm vascularizat MatriDerm [®] of resorptio The thickne week 1 to m total derma dermis was seen as the outcomes ir of daily livin study period

Trauma

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Yi C.R.	2015	Journal of Korean Burn Society	The capacity of 2mm MatriDerm® as a dermal substitute in single stage skin resurfacing	retrospective case series	5	MatriDerm® (2mm) + unmeshed STSG (compressive dressing 0.9% saline soaked gauzes)	none	one-step (with 2mm MatriDerm®)	The article m dermal subs reconstructi results show collagen and 2mm thickn making it a t the wound b returned to o defects 381
Ryssel H.	2010	Int Wound J	Single-stage MatriDerm [®] and skin grafting as an alternative reconstruction in high-voltage injuries	retrospective case series	9	MatriDerm® + STSG		one-step	The retrospe 54 who were tendons due procedure u procedures skin grafting and one pat success rate hospital stay

omes/Summary

rial compared the efficacy of dermal matrices in reducing skin res in patients with burn injuries. Patients were randomly assigned to ated with Integra®, Pelnac®, Matriderm® matrices or a control group with raft. At 12 months post-surgery, the control group had lower rates of skin raction than the matrix groups. Pelnac® resulted in larger skin graft n than Matriderm® and Integra®, while the differences between Integra® Jerm® were not significant. The study concluded that dermal matrices did or avoid the occurrence of late skin graft contraction in these patients.

study reports the successful treatment of severe contracture and a patient's right arm, shoulder, and chest using MatriDerm[®]. The patient d mobility in her shoulder and elbow, which led to scoliosis. The surgery moving scar and contracture tissue and replacing it with a dermal MatriDerm[®], which was then covered with a split-thickness skin graft. raft was well transplanted, and the patient achieved better mobility and n with daily activities. This case study highlights the potential benefit of iDerm[®] in contracture release surgery.

the study results, MatriDerm[®] showed comparable histopathological chas to normal skin, as there were no significant differences in elastin, collagen CD31, α-SMA, CD31 vessel width, stromal α-SMA, vessel quantity and width, n length. Additionally, MatriDerm[®] had significant differences in CD31 vessel compared to full-thickness skin graft (FTSG) and in CD31 vessel width com-TSG, split-thickness skin graft (STSG), and normal skin. MatriDerm[®] also had s of α-SMA stroma compared to FTSG, AlloDerm[®], and normal skin. Finally, [®] showed a similar level of collagen I to AlloDerm[®] and STSG and a signifiier level than FTSG and normal skin. These results suggest that MatriDerm[®] optimal alternative to address the cosmetic and functional limitations other treatment methods for post-burn hypertrophic scars.

as conducted in which ten sites were reconstructed with MatriDerm® mediate split thickness skin graft. Results showed evidence of early ation and an inflammatory infiltrate within the first two weeks, and ® was resorbed earlier than other dermal substitutes, with evidence on by week 3 and complete replacement by a neodermis at 2 months. ess of the dermis from the skin graft showed a significant increase from nonth 12, with the relative contribution of the skin graft dermis to the al thickness being small. Increased collagen density in the lower reticular s observed in all specimens, with collagen fragmentation and dispersion e scar matures. Patient-reported outcomes included improved in itching, pain, appearance, dryness, pliability, sensation, and activities ng. However, the mean mVSS did not show a significant change over the bod (preoperative, 7 +/- 3 versus month 12, 7 +/- 3; p = 0.310).

omes/Summary

reports on the successful use of 2mm thickness Matriderm® as a stitute in single-stage skin grafting procedures for soft tissue ion, in five patients with trauma injuries or donor site harvest. The wed good skin-quality and coverage of tissues, with more dermal d enhanced skin elasticity compared to 1mm Matriderm®. The use of ness Matriderm® reduced hospital days and decreased infection risks, time and cost-effective procedure. Grafts showed good adherence to bed 2 weeks after surgery. Success rate was 100%. all patients were daily life and work. Mean period for graft taking 12.2 days. Mean area of icm².

The retrospective analysis involved nine male patients between the ages of 19 and 54 who were referred for the reconstruction of exposed bone, joint capsule, or tendons due to severe high-voltage injuries. The patients underwent a single-stage procedure using Matriderm® and skin grafting, with a mean of 1.6 operative procedures before definite wound closure. Six of the nine patients required only one skin grafting procedure, while two patients underwent regrafting with Matriderm®, and one patient required a secondary free flap due to wound infection. The success rate was 89%, and the median follow-up was 30 months. The mean hospital stay was 61 days, with a mean rehabilitation time of 12.7 months, and 60% of the patients returned to work after treatment.

Trauma

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Cervelli V.	2011	Int Wound J	The use of MatriDerm [®] and skin grafting in post-traumatic wounds	randomized controlled trial	60	MatriDerm® + STSG (n=30)	STSG alone	one-step	Two weeks skin graft sh group. Signif associated MatriDerm®
Gümbel	2016	Journal of German Society of Dermatology	Retrospective analysis of 56 soft tissue defects treated with one-stage reconstruction using dermal skin substitutes	retrospective study	56	MatriDerm® (1mm)		one-step	In this study on both upp The graft he experienced but did not r extensive pla
Nakhi	2020	Wounds Middle East	The use of MatriDerm® and skin graft for reconstruction of complex wounds	case series	20	MatriDerm® + STSG		one-step	The use of N engraftmeni 23.7 days. O a serious lor satisfaction relatively sat MatriDerm®
Lempert	2021	Clin Case Rep	Salvage of a mangled limb with Matriderm [®] augmented split-skin grafting and maggot biodebridement	case report	1	MatriDerm® (1mm) + STSG		one-step	A case of a combination grafting, and
Lempert	2021	Langenbeck's Archives of Surgery	Long-term experience with a collagen-elastin scaffold in combination with split-thickness skin grafts for the treatment of full-thickness soft tissue defects: improvements in outcome a retrospective cohort study and case report	retrospective cohort study and case report	45	MatriDerm® + STSG		one-step	The study in different typ (MD)-augme of the treate tissue comp and 9.5% fo significantly from closed the soft tissue in a significa soft tissue c group, and -
Wallner	2022	European Journal of Trauma and Emergency Surgery	Long-term results of split-thickness skin grafting with and without additional dermal matrix in severe traumatic soft tissue defects of the lower limb	retrospective controlled	147	MatriDerm® + STSG (n=79)	STSG alone (n = 55)	One and Two step (n = 15)	The study in involved). Of alone (group with STSG ir more severe (0% had on take rate ≥ 7 compared to in wound co healing rate were necess slightly high However, in group with e (VSS) result compared to days in the H group 2 (36 In summary can be a sat skin defects
Mello	2022	Wounds https://www.hmpgloballearningnet- work.com/site/wounds/case-series/ dermal-regeneration-matrix-treat- ment-acute-complex-wounds	Dermal Regeneration Matrix in the Treatment of Acute Complex Wounds	case series	20	MatriDerm® (1mm and 2mm)	None	Yes (n=6) No (n=14)	MatriDerm® 7 to 9 days a dermal rege with no com follow-up ra evaluation re

omes/Summary

after the first treatment, 95% of wounds treated with MatriDerm® and nowed a re-epithelisation, whereas it was 75–80% in the control ficant higher percentage re-epithelialization at 3 months. All the scores with the items of Manchester Scar Scale were significantly better for group, especially in colour, appearance and contour.

y of 56 patients, the method was used successfully to cover defects ber and lower extremities, including amputation stump coverage. ealed without complication in 73.2% of patients, and only one patient d graft failure. 26.8% of patients experienced impaired wound healing require additional surgical procedures. None of the patients required lastic surgery.

MatriDerm® for reconstruction using STSG resulted in an average it rate of 80.25±32%. The mean time of complete wound healing was but of the 20 patients grafted with MatriDerm® and STSG, only one had ng-term complication, and there were no mortalities. Patient scores showed that 42% of patients were very satisfied, 36.8% were tisfied and 21% were unhappy with the outcome. The use of Preduced haematoma formation and improved scar properties.

young woman with a mangled leg that could be salvaged with a n of negative pressure wound therapy, Matriderm® augmented split-skin d maggot biodebridement.

avolving 45 wounds (44 affecting lower extremities), resulting from bes of injuries in 43 patients, found that the success rate of Matriderm® ented split-thickness skin grafting was about 90%. The recurrence rate ad wound defects that required revision surgery was 0% for the soft blications from closed fracture group, 11.1% for the open fracture group, or the soft tissue group. The duration of VAC therapy differed between the groups, with 10.8 days for the soft tissue complications I fracture group, 22.7 days for the open fracture group, and 12.6 days for ue group. The use of negative pressure wound therapy (NPWT) resulted ant reduction of bioburden, with a bacterial shift of -2.25 (1.89) for the complications from closed fracture group, -1.9 (1.37) for the open fracture -2.6 (2.2) for the soft tissue group.

ncluded a total of 147 cases (134 patients and 13 patients with both legs f these, 63 soft tissue defects in 55 patients were treated with STSG p 1), while 84 severe soft tissue defects in 79 patients were treated n combination with MatriDerm® (group 2). The wounds in group 2 were e (85% had exposed tendon, muscle, or bone) compared to group 1 ly dermis involved). The overall healing rate (number of patients with 75%) was 88/147 (60%). In group 1, the healing rate was 42/63 (67%) o group 2, with a healing rate of 46/84 (55%) (p=0.15). The difference mplexity between the treatment groups did not significantly impact the or the scar tissue quality 12 months postoperatively. Surgical revisions sary in about 25% of the cases, with the number of revisions being er in group 2 (3.4 ± 2.4) compared to group 1 (2.6 ± 1.5 ; p = 0.03). the subgroup analysis depending on different exposed soft tissues, the exposed muscle showed a trend towards better Vancouver Scar Scale s after using STSG in combination with MatriDerm[®] (VSS=4.4 points) o STSG only (VSS = 5.3 points) (p = 0.112). Additionally, the number of hospital was significantly less in group 1 (26 days ±17 days) than in ±19 days) (p=0.001), indicative of the difference in wound severity. , the study suggests that STSG and additional MatriDerm® application tisfactory alternative for dermis replacement in patients with severe

⁹ 1 and 2mm, when used in a two-step procedure with skin grafting after and combined with negative pressure wound therapy (NPWT), achieved eneration and skin graft integration rates of almost 100% in all cases, applications. The Vancouver Scar Scale (VSS) scores at a 12-month anged from zero to 6 (average, 2.25 \pm 0.65), indicating good subjective esults in terms of integration of MatriDerm[®] and skin grafts.

Soft tissue defects

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Heckmann A.	2011	Der Unfallohirurg	One-stage defect closure of deperiosted bone and exposed tendons with MatriDerm® and skin transplantation. Possibilities and limitations [article in German]	prospective, case series	10	MatriDerm®	none	two-step (two-stept in all cases)	In nine of te wound clos could be ac successful i a second sk of the four l skin transpl complex pla
Pasternak I.	2014	52. Jahrestagung der ÖGPÄRC	Subcutane Polsterung des Ramus superficialis Nervi radialis mit MatriDerm® Ein Fallbericht [article in German]	case report	1	MatriDerm [®]	none	one-step	MatriDerm [®] R. superfici
Morozzo U.	2015	Indian J Surg	Soft tissue reconstructions with dermal substitutes versus alternative approaches in patients with traumatic complex wounds	prospective	52	25 (standard choice Integra®) mean age 50 years	27 gold standard (local flaps, free flaps, dermo- epidermal autografts) mean age 44 years	one-step (only with MatriDerm®)	Patients wit (67.7 versus less invasive more patho
De Vries H.	1995	British Journal of dermatology	Reduced wound contraction and scar formation in punch biopsy wounds. Native collagen dermal substitutes	prospective, intra- individual study	8 (7)	native collagen sponge	no treatment; collagen sponge coated with alpha-elastin; coated with fibronectin, coated with hyaluronic acid	n.ap	Wounds ep tion: 20% v and coated were detect ges collage elastin coat
Abed S.	2014	Annales de Dermatologie et de venereologie	The place of skin substitutes in surgical treatment of necrotizing cellulitis: Seven cases [French]	case series	7	MatriDerm® + STSG (1 patient) and Integra® (6 patients)		one-step (Integra® 2 step)	Excellent el second tim MatriDerm [®]
Gümbel	2016	Journal of German Society of Dermatology	Retrospective analysis of 56 soft tissue defects treated with one-stage reconstruction using dermal skin substitutes	retrospective study	56	MatriDerm [®] (1mm)		one-step	In this study both upper healed with graft failure. additional su
Vilela	2017	World Neurosurgery	Matriderm [®] for the management of scalp necrosis following surgical treatment of a giant parietal encephalocele.	case report	1	MatriDerm [®] (1mm) + STSG		one-step	The use of I split-thickne and resulter further com
Mitwalli	2019	Egypt J Plast Reconstr Surg	Evaluation of the use of single stage dermal substitutes in acute and chronic wounds of the hands	comparative clinical study	85	MatriDerm® (1mm) + STSG (n=55)	STSG alone	one-step	The study ir outcomes v nation, rang 21-25 days scores for N satisfaction substitutes alone, with p
Hones	2023	Jounral of wound care	Treatment of complex extremity wounds with MatriDerm®: first clinical experience in the US	retrosprective case Series	11	MatriDerm®		two-step n=6 without grafting n=2 with delayed grafting	The study m treatment of social issue structures e (n = 7). The eight wound The mean t 49 days (ra required de coverage in
Lee	2023	Annals of Plastic Surgery	Management of Hardware-Exposed soft Tissue Defects Using Dermal Substitutes and Negative Pressure Wound Therapy	retrospective case series	14	MatriDerm®		one-step	14 patients were treate ment, Matri duration of injury type, more replac changes wi grafting witt NPWT and wounds, wh

en patients complete defect coverage could be achieved. A one-stage sure in extensive defects with exposed tendons in four of five locations chieved. In deperiosted bone defects the one-stage coverage was only I in two of six patients. Complete wound closure could be achieved with skin transplantation in patients with exposed tendon and bone in three locations. As a one or two stage procedure MatriDerm® application with olantation resulted in an effective defect closure without the need for an lastic reconstructive procedure.

[®] was used for successful augmentation of the subcutis cushioning alis n. radialis.

th dermal substitutes experienced a generally faster healing process s 70.1 days), reduced overall hospitalization time (9.71 versus 9.96 days), re procedure, significant lower surgery time ((46.3 versus 142.8 min)), plogical scarring, less surgical costs (5672.14 ± 2900.1 6369.44 ± 3062.1).

bithelialized in 7-10 days. Control wounds showed most wound contracwith significant difference between control and coated with fibronectin d with elastin. After 6 weeks no collagen fibers from dermal templates sted anymore. Fibronectin and elastin coated groups showed rete-riden bundles, indicating better dermal-epidermal connection. At 3 months ted group showed collagen network similar to normal dermis.

lasticity and flexibility. Good recovery and functionality. No need for ne general anesthetic with MatriDerm[®]. Example of clinical case with [®] and exposed tendon.

y of 56 patients, the method was used successfully to cover defects on and lower extremities, including amputation stump coverage. The graft nout complication in 73.2% of patients, and only one patient experienced 26.8% of patients experienced impaired wound healing but did not require urgical procedures. None of the patients required extensive plastic surgery.

MatriDerm[®] layered directly over the brain tissue in combination with a ness skin graft proved to be a simple technique with minimal morbidity ed in a stable wound with a good result (rapid engraftment, without any mplications, with an acceptable cosmetic result in long term follow-up)

ncluded 85 adult patients with acute and chronic hand wounds. The were assessed using the Vancouver Scar Scale, histopathological examige of motion, and patient satisfaction. Complete healing time between in both groups. Regrafting needed in 4 patients (7%). Significant VSS MatriDerm® group (4.9 + / - 0.8). 100% patient satisfaction: 45%; 80% n: 45% Histology confirms newly formed dermis. The use of dermal showed significant differences in outcomes compared to skin grafting promising results reported for acute burns and chronic wounds.

reviewed the first US inpatient clinical experience with MatriDerm® for of such difficult wounds in 11 patients with medical comorbidities or es. The wounds were in the forearm, hand, leg, and feet, with vital exposed that included bone (n = 3), tendon and bone (n = 1), and tendon mean area of the wounds was 59.2 cm² (range: 2 to 230). In the series, nds healed, six with MatriDerm® only and two after delayed skin grafting. time to wound healing in patients treated with MatriDerm® only was ange: 7 to 84), and 44.5 days (range: 32 to 57) in the two patients who elayed skin grafting. MatriDerm® has potential as an alternative to flap n patients who are not good candidates for flap surgery.

with hardware-exposing wounds after internal fixation using plates ad with the wound management procedure, involving surgical debrideiDerm® placement, and negative pressure wound therapy (NPWT). The treatment and number of NPWT replacements were stratified based on with open fractures requiring significantly longer NPWT and undergoing cements. Patients with open fractures underwent a mean of 6.6 NPWT hile those with closed fractures underwent 2.5 (P = 0.002). However, skin th MatriDerm® was successful in all 14 patients. The study reveals that MatriDerm®-augmented skin grafting are useful for hardware-exposed here flap surgery has been considered the only treatment.

Donor sites

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outc
Park T.	2015	Maxillofacial Plastic and Reconstructive Surgery	Double layered collagen graft to the radial forearm free flap donor sites without skin graft	case series	22	MatriDerm® (bottom) in combination with Terudermis (top)	none	one-step	The scar and ned betweet defect or in aesthetic a ing and ave MatriDerm
Dunne J.	2014	ePlasty	A previously discounted flap now reconsidered: MatriDerm® and split-thickness skin grafting for tendon cover following dorsalis pedis fasciocutaneous flap in lower limb trauma	case report	1	MatriDerm® + STSG		one-step	MatriDerm foot had ex range of m
Min J.	2014	Arch Plast Surg	The Use of MatriDerm® and Autologous Skin Graft in the Treatment of Full Thickness Skin Defects	retrospective case series	31	MatriDerm® + STSG		one-step	Graft surviv value of the water loss erythema a When com MatriDerm significant o
Watfa	2017	J Sex Med	MatriDerm® Decreases Donor Site Morbidity After Radial Forearm Free Flap Harvest in Transgender Surgery	retrospective nature of the prospective database	37	split thickness skin graft with MatriDerm® (n=29)	full-thickness skin graft (n = 8)	one-step	In a study e donor sites full or partia one patient affect graft sensory ret Semmes-V compared addition, th group (0.43 were also s these findir decreased
Cristofari	2019	ANNPLA	Coverage of radial foream flap donor site with full thickness skin fragt and MatriDerm®: An alternative reliable solution?	retrospective comparative study	43	MatriDerm® + FTSG and MatriDerm® + STSG	FTSG	one-step	Study yo ev using full-th FTSG with aesthetic m DASH scor patient sat MatriDerm satisfactior (1 month po and VSS so satisfactior
Abbate	2020	The Journal of Craniofacial Surgery	The use of dermal substitutes for Donor Site Closure After Radial Forearm Free Flap Harvesting	retrospective study	18	MatriDerm® + STSG (1mm, n=9)	STSG	one-step	The study a closure and obtained a in circumfe significant (average Va group com Shoulder, a compared
Burger	2023	Indian J Surg	Donor Site Defect Coverage of the Forearm with Dermal Substitute After Harvesting Radial Forearm Free Flap for Phalloplasty: Is MatriDerm® Worth the Effort?	case series	42 (21/21)	MatriDerm®	FTSG	one-step	The use of decreased reoperatior MatriDerm ⁴ neuromas on for Matr In comparis grades 4-5 is consider

omes/Summary

rea was decreased to 63.9% in average. The complete healing was obtaien 1.5 and 3 months according to the defect size. There was no functional mpairment 3 months after operation. Patients were satisfied with the and functional results Major advantage: skip surgical step for STSG harvestoid STSG donor site morbidity, delayed healing period compared with 1[®] in combination with STSG (over 3 months compared with 4-6 weeks).

[®] successfully used at donor site. Three months postoperatively, the xcellent function and cosmesis, with toes in a neutral position and a full novement.

val rate 96.7%. Wound epithelialization within 2 weeks. The elasticity e portion on which MatriDerm[®] was applied was 0.765, trans-epidermal was 10.0 g/hr/m², and the humidification value was 24.0. The levels of and melanin were 352.0 arbitrary unit (AU) and 211.0 AU, respectively. aparing the values of elasticity and TEWL of the skin treated with [®] to the values of the surrounding skin, there was no statistically difference between the groups.

evaluating the use of MatriDerm[®] for radial forearm free flap (RFFF) s, favorable outcomes were reported. All 37 patients survived, with no ial necrosis reported. Donor site complications were minimal, with only it in the dermal substitute group experiencing a hematoma that did not t take. Sensory outcomes were particularly favorable, with better turn in the dermal substitute group as demonstrated by an average Neinstein monofilament value of 6.96 ± 1.11 for A1 and 7.27 ± 1.12 for A2, to 14.26 ± 2.07 for A1 and 15.58 ± 1.43 for A2 in the FTSG group. In ne average DASH score was significantly lower in the dermal substitute 3 ± 0.15) compared to the FTSG group (14.17 ± 3.83), and esthetic scores significantly higher in the dermal substitute group (P < .0001). In conclusion, ngs suggest that the use of MatriDerm[®] for RFFF donor sites can lead to I morbidity and improved clinical outcomes.

valuate a new technique for forearm coverage with artificial dermis, hickness skin graft (FTSG) with Matriderm[®]. The study showed that Matriderm[®] resulted in improved residual functionality, skin quality, result, and satisfaction scores compared to other techniques. The mean re was 10.6/100 and the mean VSS score was 5.5/13. Mean surgeon and tisfaction scores were 3/5 in the FTSG with Matriderm[®] group. FTSG + [®] showed improved DASH (11/100) and VSS scare (6/13), mean surgeon n scar 3/5 (5 best), mean patient satisfaction 3/5 (5 best); Take rate ost-op): 89,6%. STSG + MatriDerm[®] showed improved DASH (17/100 core (7/13), mean sugeon satisfacion score (2,64/5), mean patients n 2,42/5; Take rate (1 month post-op): 86,7%.

analyzed 18 patients and compared the outcomes between a STSG d the use of MatriDerm[®]. Patients treated with MatriDerm[®] + STSG better result in both aesthetic and functional outcomes. The difference prences between the operated and contralateral limbs was statistically (P < 0.004) with a difference of 1.2mm proximal and 1.3mm distal. The ancouver Scar Scale (VSS) was 1.75 ± 0.2 for the MatriDerm[®] + STGS pared to 1.82 ± 0.2 for the STSG group. The Disabilities of the Arm, and Hand (DASH) score was 19.4% in the MatriDerm[®] + STGS group to 21.8% in the STSG group.

MatriDerm® in phalloplasty donor site defect coverage significantly the incidence of complications, including wound healing disorders and n rates, compared to full-thickness skin grafts from the groin area. ® showed an average duration of hospital stay of 20 days, with no reported of the superficial branch of the radial nerve. The Clavien-Dindo classificatiriDerm® resulted in 20 grade 0,1 grade 1, and no grades 2-5 complications. son, the FTSG resulted in 16 grade 0,3 grade 1,0 grade 2,2 grade 3, and no 5 complications. Overall, the use of dermal templates such as MatriDerm® red worth the additional effort and costs in this patient population.

Cancer excisions

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Healy C.	2011	BAPRAS (British Association of Plastic, Reconstructive and Aesthetic Surgeons) Meeting [Abstract]	Improving Reconstruction of Skin Cancer Excision Defects with Single-Stage Artificial Dermal Substitute (MatriDerm®) and Thin Split-Skin Graft	case series, retrospective analysis	70	MatriDerm® + thin split-thickness skin graft	none	one-step	The majorit contracture defect to w were no loc template ap terms of co
Pauchot J.	2012	Dermatol Surg	Dermal equivalents in oncology: benefit of one-stage procedure.	retrospective case series	16	MatriDerm [®] + STSG	Integra®	MatriDerm [®] 1-step, Integra [®] 2-step	Wound hea Three cases MatriDerm [®] Mean healir
Bertolli E.	2013	Int Wound J	Artificial dermis (MatriDerm®) followed by skin graft as an option in dermatofibrosarcoma protuberans with complete circumferential and peripheral deep margin assessment.	case report	1	MatriDerm [®] (2mm) alone		n.ap	MatriDerm [®] defect. At 4
Lamy J.	2013	Ann Chir Plast Esthet	[Use of MatriDerm [®] 1mm in reconstructive surgery. Series of 31 cases]. [Article in French]	prospective case series	28	MatriDerm [®] + STSG		one-step	The use of 1 patients wit extended b sequels, or of 87 +/- 19 aesthetic a
Kappos E. (Kalbermatten)	2014	Case reports in Medicine	Bovine Dermal Matrix as Coverage of Facial Nerve Grafts	case report	1	MatriDerm [®] + STSG		one-step	The use of I alternative f nerve grafts Aesthetic re
Park	2016	Arch Craniofac Surg	Immediate Near-Total Scalp Reconstruction with Artificial Dermis on Exposed Calvarium	case report	1	MatriDerm [®] and meshed STSG		one-step	In a 78-year of a large so following wi complicatio
Pauchot	2016	Annales de chirurgie plastique esthétique	Conformation du lambeau antébrachial en arche sur mesure pour la reconstruction du voile du palais. Cas clinique	case report	1			one-step	MatriDerm [®] flap design
Campagnari	2017 a	International Journal of Surgical Oncology	Dermal Substitutes Use in Reconstructive Surgery for Skin Tumors: A Single-Center Experience	single-center study	13	MatriDerm® (n = 12) Integra® (n = 1)		two-step	This article reconstruct diagnosis w were the sc (46.2%) an grafting wa wound com substitutes surgery for one patient
Wollina U.	2017 a	Maced J Med Sci	Very Rare Amelanotic Lentigo Maligna Melanoma with Skull Roof Invasion	case report	1	MatriDerm® + meshed skin graft		one-step	In a 73-year skin coloure defect was graft. Healir the skin tran closed by s
Mahabbat	2018	ePlasty	Functional Subunit Reconstruction of Giant Facial Congenital Melanocytic Neci in Children With the Use of Matriderm [®] and Skin Graft: Surgical Experience and Literature Review	case report	1	MatriDerm® + STSG		one-step	A case stuc was presen scalp skin g scar and no postoperati Resection c truction usi method wit cal outcom

omes/Summary

ity of patients had an excellent cosmetic result with reduced wound re, improved skin pliability and elasticity and markedly reduced contour what would be expected with a split-thickness skin graft alone. There cal or systemic allergic complications associated with the MatriDerm[®] application. Marked improvement in the quality of the reconstruction in ontour defect, skin elasticity, and graft stability.

aling times with MatriDerm[®] were 4 weeks less than those with Integra[®]. as of infection were noted with Integra[®] (75%), versus 0% with [®]. Times to skin grafting with Integra[®] were between 3 and 8 weeks. ng time: 10 weeks.

⁹ 2mm was used prior to final reconstruction, to cover the exposed skull weeks the wound was completely granulated. Incl. case photo's.

1mm MatriDerm[®] has been evaluated for reconstructive surgery in th tissue losses after limb or trunk sarcoma resection, melanoma, paso- or spinocellular carcinoma, palmoplantar keratodermy, burn traumatic tissue losses. The results showed a mean taken rate 9% of the area, a mean day of discharge of 4.8 days, and satisfying and functional results. Mean costs/patient: Euro 906.5.

MatriDerm[®] and split thickness skin graft was a safe, easy, and fast for covering soft tissue defects, even on wound grounds containing is. No postoperative complications were reported. Uneventful healing. esult and soft tissue mobility acceptable.

ur-old woman, successfull perfomance of a single-stage reconstruction calp defect using a combination of MatriDerm[®], split-thickness skin graft ide excision of a cutaneous angiosarcoma. No wound infection or other ons reported up to 13 month postoperatively.

⁹ is used to cover the doner site (60-year-old male) of a "double-arched" for reconstructing soft palate defects after oncologic resection.

e reports on a single-center experience using dermal substitutes in ptive surgery for skin malignancies. Among 13 patients, the most common was basal cell carcinoma (38.5%), and the most frequent sites of injury calp (53.8%) and lower limbs (23.1%). The use of MatriDerm® 2 mm nd NPWT (46.2%) were common. The average time to second-stage skin as 43.9 days, and the most frequent complication of the first stage was ntamination (38.5%). The study concluded that the use of dermal s provides good aesthetical and functional results in reconstructive r skin malignancies. Three patients experienced tumor recurrence, and it died due to disease progression.

ur-old male patient LMM was removed by slow Mohs. 1 year later, another ed nodule of the bald head was removed by slow mohs surgery. The closed by sandwich transplantation with MatriDerm® and meshed skin ng was uneventful. Again 1 year later, a firm tumour proliferation around unsplant occures (LMM). Wide excision of the tumor. Defect was again candwich transplantation.

dy of an 8-year-old boy with a facial giant congenital melanocytic nevus nted. The surgical reconstruction involved the use of a partial-thickness graft aided with Matriderm[®] dermal substitute, resulting in a favorable to donor site complications such as alopecia or hypertrophic scar. The tive result was satisfactory with minimal residual nevus around the eye. of facial congenital melanocytic nevi, followed by single-stage reconssing Matriderm[®] and skin graft, is an excellent and fast reconstructive th promising aesthetic outcomes and greater improvement in physiologine, especially in the pediatric population.

Cancer excisions

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Moon	2019	PRAS	Tissue-engineered dermis grafts using stromal vascular fraction cells on the nose: A retrospective case-control study.	retrospective case control study	47	MatriDerm® (3-5 layers)	MatriDerm [®] + SVF cells	two-step	This study of (SVF) cells carcinoma a significan dermis grou (POSAS) (P evaluation (significant a 35.0 ± 17.5 n
Sang-Woo Kang	2019	Cancer Management and Research	Skin graft using MatriDerm® for plantar defects after excision of skin cancer	case report	2	MatriDerm®		two-step	Clinical out - 66 year of Bowen's de - plantar fa skin defect + STSG - 8 weeks a functional p which grad Case 2: - 69 year of - wide excis weeek later - complete
Shay	2019	Journal of Craniofacial Surgery	One-Step Triple-Layer Reconstruction of an Exposed Calvarium in a Radiated Tinea Capitis Patient	case report	1	MatriDerm [®]		one-step	A 78-year of multilayered cover the e flaps and a 4: MD+STS wound. 16 v recurrence aesthically avoiding un
Dell' Aversana Orabona	2022	J Clin Med	The Use of MatriDerm® for Scalp Full-Thickness Defects Reconstrution: A Case Series	retrospective case series	16	MatriDerm® + STSG		one-step (2 Two-Step)	A study wat tumor excis split-thickn Scale. The r surrounding 6 months a evaluate th and 1 year. 2, indicating were obser
Na	2022	Archives of Craniofacial Surgery	Scalp reconstruction using the reverse temporalis muscle flap: a case report	case report	1	reverse temporalis muscle flap and MatriDerm® in exposed area + STSG	none		MatriDerm [®] graft RTFM flap, Matrid cover. The p allowed for
Tran	2022	Cureus	Large Scalp Defect Reconstruction With Tissue Expansion, Orticochea Flap, and Acellular Dermal Matrix for Soft Tissue Augmentation: A Case Report	case report	1	MatriDerm® + Orticochea flap	none		A case repo underwent a large full-1 flaps and M improved h there was r
Paganelli (Magnoni)	2023	Life	Wound Healing after Acellular Dermal Substitute Positioning in Dermato-Oncological Surgery: A Prospective Comparative Study	prospective comparative study (intra- individual)	10	MatriDerm®	Integra®	two-step, after 3 weeks	MatriDerm ⁴ surgeries. A differences neoformed while Integr into the wo scores wern Integra®: VS evident in fo evaluation n with faster some case colonized b

omes/Summary

compared tissue-engineered dermis with stromal vascular fraction to artificial dermis to cover defects after surgical excision of basal cell on the nose in 77 patients. The tissue-engineered dermis group showed thy lower total scar assessment score (11.3 \pm 2.0) than the artificial pup (12.8 \pm 2.9) in the Patient and Observer Scar Assessment Scale P = 0.031) and lower total scores regarding the observer-assessed OSAS (11.2 \pm 1.8 vs. 13.1 \pm 3.6, P = 0.028). All grafts were successful, with no adverse events or BCC recurrence during a mean follow-up period of months. The time for re-epithelialization in the two groups was similar.

tcomes Case 1:

old woman, chronice ulceration on the plantar surface for 8 month, esease; photodynamic therapy, + wide excision of cancer. ascia and lateral plantar neurovascular bundle were exposed through t; covered with MD + NPWT; NPT changed every week; one week later

after surgery: complete healing; no complication (like infection); no problems of the foot; numbness on the distal lateral side of the food, dually improved

old male; pigmented skin lesion; melanoma

ision; plantar fascia was exposed; covered with MatriDerm® + NPWT; one er + STSG

healing after 6 weeks; no complications, no functional problems

old femal with sqamous cell carcinoma: Cancer excision and 1-stage ad surgical reconstruction which included 3 pericranial turnover flaps to exposed calvarium, MatriDerm[®], which was placed above the pericrania a split-thickness skin graft to cover the entire defect. On post-OP day SG were stable and intact. 3 weeks post-OP: complete healing of the weeks post-OP: no signs of wound breakdown nor signs of tumor a. This technique provides an improved outcome, structurally and when compared with other dermal substitutes-based techniques, while nnecessary burring of the outer table of the calvarium.

as conducted on 16 patients who underwent scalp full-thickness ision and reconstruction using Matriderm® dermal substitute and ness skin graft. The outcomes were evaluated using the Vancouver Scar results showed optimal wound healing, grafted skin similar to ng tissue, and a decrease in pigmentation and vascularity between and 1-year follow-ups. The Vancouver Scar Scale (VSS) was used to ne surgical outcome during follow-ups recorded at 1 month, 6 months, The mean VSS score at 1 year was 16,875 with a range between 0 and g a significant improvement in scar status. The highest improvements rved in pigmentation and vascularity.

[®] was used in reconstructing a scalp ulcer due to partial loss of a skin I (reverse temporalis muscle flap) was used as an alternatve to a free derm[®] was used to cover the area that the RTMF did not completely procedure was successful, the wound healed well, and MatriDerm[®] r soft-tissue coverage and volume restoration.

ort on a 53-year-old patient with skin cancers on the scalp. The patient t tissue expansion and Mohs surgery to remove the tumors and create -thickness skin defect, which was then reconstructed with Orticochea MatriDerm[®] graft. The MatriDerm[®] graft was placed centrally for nealing and circulation. During the one-month postoperative follow-up, no evidence of wound breakdown, infection, or necrosis.

MatriDerm® and Integra® are ADMs commonly used in dermato-oncological surgeries. A study compared the two ADMs in 10 patients and found no significant differences in final clinical outcomes or extracellular matrix content of the neoformed dermis. However, MatriDerm® induced scar retraction more frequently, while Integra® was associated with higher infectious risk and slower reabsorption into the wound bed, along with foreign body-like granulomatous reactions. The VSS scores were comparable between the two ADMs (MatriDerm®: VSS: 6,1+/-1,6 (3-8); Integra®: VSS: 5,7+/-1,9 (2-8)), though more evident wound bed contracture was evident in four cases in areas treated with MatriDerm® (p < 0.05). Histopathological evaluation revealed that MatriDerm® was reabsorbed more quickly than Integra®, with faster maturation of the granulation tissue and re-epithelization observed in some cases. The infection rate was higher in Integra®, which was more easily colonized by bacteria. Overall, both ADMs had similar vascularization of the wound bed and collagen/fibronectin content.

Chronic wounds

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Jeon H.	2013	Arch Plast Surg	Treatment of diabetic foot ulcer using MatriDerm [®] in comparison with a skin graft	prospective controlled	60	MatriDerm® + STSG (n=30)	STSG alone (n=30)	one-step	MatriDerm [®] (p < 0.05); 9 (elasticity ra STSG alone 80% comp
Cervelli V.	2010	Int Wound J	The use of MatriDerm [®] and autologous skin grafting in the treatment of diabetic ulcers: a case report	case report	1	MatriDerm [®] + STSG		one-step	DFU of 35x completely obtained a reduction ir of the missi of surgical p
Wollina U.	2011	J Cutan Aesthet Surg	One-stage Reconstruction of Soft Tissue Defects with the Sandwich Technique: Collagen-elastin Dermal Template and Skin Grafts	prospective case series	23	MatriDerm® + STSG		one-step	Use of a sau grafts to tre tendons. The granulation 19 achieving days. Stable very good o good aesthe template us intermittent
Wollina U.	2011	Int Wound J	Use of a collagen-elastin matrix for hard to treat soft tissue defects	case series	6	MatriDerm [®] + STSG		one-step	MatriDerm [®] with deep s outcomes v wound clos no adverse
De Angelis B.	2013	J Tissue Engineering	Chronic ulcers: MatriDerm [®] system in smoker, cardiopathic, and diabetic patients	case report	1	MatriDerm [®] + STSG		one-step	MatriDerm [®] function res
Mandel	2018	J Wound Care	Treatment of chronic infected post-oncological wounds with a dermal matrix: two case studies	case serie	2	MatriDerm®		two-step	Case 1: 76 y Two recons Surgical hypost-surgic same dress surgeon an- Case 2: 46 bullosa: rec graft with a reconstruct Summary: o colume and
Wollina U.	2018	Maced J Med Sci	The Role of Complex Treatment in Mixed Leg Ulcers - A Case Report of Vascular, Surgical and Physical Therapy	case report	1	MatriDerm [®] + meshed STSG		one-step	A case repo arterioveno stable wour insufficiency transcutane by sandwic patient had
Mitwalli	2019	Egypt J Plast Reconstr Surg	Evaluation of the use of single stage dermal substitutes in acute and chronic wounds of the hands	comparative clinical study	85	MatriDerm® (1mm) + STSG (n=55)	STSG alone	one-step	The study ir outcomes v examination between 21 Significant v 100% patien Histology of significant of results repo
Buzea	2020	Journal of Clinical and Medical Images	Oneßstage closure of venous ulcers with MatriDerm® and Split Thickness Skin Grafts	case report	2	MatriDerm [®] + STSG and compresseion therapy		one-step	The article i and split-th compressic 1 month, 3 r MatriDerm [®]

omes/Summary

[®] group: LoS: 7.52 weeks (p < 0.05); wound epithelialization: 8.61 weeks 03.3% completely healed (p < 0.05); significant higher elasticity atio 0.72 (affected/non-affected side)) e: LoS: 9.22 weeks; wound epithelialization: 12.94 weeks; bletely healed; (elasticity ratio 0.19 (affected/non-affected side)).

x25cm, with prior Gentamycin treatment. 7 days post-op skin graft not taken, 14 days post-op total integration. After just a single treatment, reduction in ulcer after 15 days from the surgical treatment. Achieved a n pain and exudate secretion of the ulcer. Almost complete restoration ing volume and good quality of skin. Case includes extensive description procedure. Wet application of MatriDerm[®].

andwich technique combining a dermal collagen-elastin matrix with skin eat full-thickness soft tissue defects with exposed bone, cartilage, or he use of the dermal template resulted in a complete and stable n in 100% of wounds, with 17 defects showing complete closure and ag complete granulation with an incomplete closure. Healing time 9-14 le wound closure with very good aesthetic outcome. 74% of patients had or good aesthetic outcome. There was also a marked pain relief and a netic outcome. No adverse events were noted due to the dermal issage, and the technique can be easily used in conjunction with nt negative pressure when necessary.

[®] in combination with meshed skin grafts was assessed in six patients soft tissue defects that had exposed tendons, cartilage or bone. The were promising as healing was uncomplicated in all patients, complete sure was achieved, and the use of MatriDerm[®] reduced healing time with effects such as skin contracture.

⁹ with STSG used in a chronic ulcer. Decrease of limb oedema, full stored. Skin volume restored and improvement of texture.

year old male with chronic ulcer on the lateral region of the richt thigh. struction procedures with a skin graft and dermal matrix fails before. /drodebridement and reconstruction with dermal matrix, followed by the cal dressing protocol. Neodermis was covered with STSG, followed by the sing protocol. uneventful course, result was very satisfactory to both the nd the patient.

old mal with laminin-332-deficient non-Herlitz junctional epidermolysis construction with a Integra® failed. sugical hydrodebridment and a new a dermal matrix followed by postoperative dressing protocol. No tion with skin graft, therefore the wound healed by secondary intention. complete wound healing, alsmost complete restoration of the missing d good quality of grafted skin.

ort of an 80-year-old female patient with a chronic leg ulcer of mixed ous origin on the left lower leg. The aim was to achieve complete and nd closure despite arterial occlusion, exposed tendon, and renal by Benefits reported included percutaneous transluminal angioplasty, ieous CO2, and deep ulcer shaving leading to successful wound closure och transplantation using MatriDerm® and meshed split skin graft. The d a 100% graft take with rapid reduction of severe wound pain.

ncluded 85 adult patients with acute and chronic hand wounds. The were assessed using the Vancouver Scar Scale, histopathological in, range of motion, and patient satisfaction. Complete healing time 1-25 days in both groups. Regrafting needed in 4 patients (7%). VSS scores for MatriDerm[®] group (4.9 +/- 0.8). ent satisfaction: 45%; 80% satisfaction: 45%

onfirms newly formed dermis. The use of dermal substitutes showed differences in outcomes compared to skin grafting alone, with promising orted for acute burns and chronic wounds.

reports on two cases of large venous ulcers treated with MatriDerm® nickness skin grafts in a one-stage procedure, combined with on therapy. Graft take at day 5 was 100%, and follow-ups at 2 weeks, months, and 6 months revealed no signs of recurrence. The use of ® in a one-stage procedure could lead to reduced hospitalization costs.

Tendon/Adhesion barrier

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Morozzo U.	2015	Indian J Surg	Soft tissue reconstructions with dermal substitutes versus alternative approaches in patients with traumatic complex wounds	prospective	52	25 (standard choice Integra®) mean age 50 years	27 gold standard (local flaps, free flaps, dermo- epidermal autografts) mean age 44 years	one-step (only with MatriDerm®)	Patients wir (67.7 versus less invasiv more patho
Petschke F.	2015	JPRAS Open	Novel Tortilla method for applying MatriDerm [®] around dissected nerves and tendons	case report	1	MatriDerm®	none	one-step, applied as protective matrix	This novel r of the disse
Wetzig T.	2009	Dermatology	New indications for artificial collagen-elastin matrices? Covering exposed tendons	case report	1	MatriDerm® + STSG		one-step	80 year old hand. Expo promising r
Ryssel H.	2010	Int Wound J	Single-stage MatriDerm [®] and skin grafting as an alternative reconstruction in high-voltage injuries	retrospective case series	9	MatriDerm® + STSG		one-step	The retrosp 54 who wer tendons du procedures skin graftin and one pa success rat hospital sta of the patie
Abed S.	2014	Annales de Dermatologie et de venereologie	The place of skin substitutes in surgical treatment of necrotizing cellulitis: Seven cases [French]	case series	7	MatriDerm® + STSG (1 patient) and Integra® (6 patients)		one-step (Integra® 2 step)	Example of and flexibilition anesthetic
Graf	2017	White Paper	First experiences with the use of MatriDerm [®] in the prevention of tendon adhesions in foot surgery	retrospective case series	11	MatriDerm [®]			All patients complication
Gonzalez- Quevedo	2020	THE BONE & JOINT JOURNAL	Improving the regenerative microenvironment during tendon healing by using nanostructured fibrin/agarose-based hydrogels in a rate Achilles tendon injury model	animal		MatriDerm®	nanostructured fibrin-agarose hydrogel (NFAH) or genipin cross- linked nanostructured fibrin-agarose hydrogel (GP-NFAH)		The study in tendon hea significantly repaired ten organization histological
Shim	2021	Journal of Wound Care	Preventing postoperative adhesions after hand tendon repair using acellular dermal matrix	Prospective open trial, case-control study	37	with MatriDerm® (acellular dermal matrix)	without ADM	one-step tendon repair	The use of 1 adhesions a motion in th and 75.8 ± 6 different (p 79.9 ± 7.1 in statistically higher in th versus 215.1 Satisfactior ADM group

omes/Summary

ith dermal substitutes experienced a generally faster healing process s 70.1 days), reduced overall hospitalization time (9.71 versus 9.96 days), ve procedure, significant lower surgery time ((46.3 versus 142.8 min)), ological scarring, less surgical costs (5672.14±2900.1 6369.44±3062.1).

method offers an easy technique to achieve a complete coverage ected structure.

d patient, with co-morbidities with defect due to carcinoma on osed tendons. Wet application of MatriDerm[®]. After 7 days and 3 weeks results. Completely healed at 6 months.

pective analysis involved nine male patients between the ages of 19 and ere referred for the reconstruction of exposed bone, joint capsule, or ue to severe high-voltage injuries. The patients underwent a single-stage using Matriderm® and skin grafting, with a mean of 1.6 operative es before definite wound closure. Six of the nine patients required only one ng procedure, while two patients underwent regrafting with Matriderm®, atient required a secondary free flap due to wound infection. The ate was 89%, and the median follow-up was 30 months. The mean ay was 61 days, with a mean rehabilitation time of 12.7 months, and 60% ents returned to work after treatment.

f clinical case with MatriDerm[®] and exposed tendon. Excellent elasticity lity. Good recovery and functionality. No need for second time general with MatriDerm[®].

s had a very satisfactory functional outcome and no post operative ons were mentioned that were related to the use of MatriDerm[®].

investigated the effect of MatriDerm®, NFAH and GP-NFAH on Achilles aling in rats. The results showed that NFAH and GP-NFAH had ly higher tensile strength compared to MatriDerm®. In vivo evaluation of endons using NFAH, GP-NFAH and MatriDerm® resulted in better on of collagen fibers and cell alignment than direct repair, with a better al score in GP-NFAH.

MatriDerm[®] as a preventative measure for postoperative tendon after tendon injury was studied. At six months after surgery, the range of the proximal interphalangeal joint was 81.0 ± 5.1 degrees in the ADM group 6.9 degrees in the control group, which was statistically significantly > = 0.03). In the distal interphalangeal joint, the range of motion was the ADM group and 71.2 ± 5.7 degrees in the control group, which was y significantly different (p < 0.05). In addition, the total active motion was the ADM group compared with the control group (231.5 ± 12.5 degrees 1 ± 17.1 degrees, respectively, p = 0.04). Patients' scores from the Patient in Questionnaire were also significantly different, namely 8.9 ± 1.0 in the o and 7.8 ± 1.4 in the control group (p = 0.02).

Miscellaneous

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outc
Cervelli V.	2012	Int Wound J	Skin necrosis of scrotum due to endovascular embolisation: a case report	case report	1	MatriDerm® + split-thickness autograft	none	one-step	The skin wa appeared to compared amelioratic scar tissue no evidence discomfort
Djedovic G.	2015	Eur J Plast Surg	Use of an acellular dermal template for defect coverage on the penile shaft	case report	1	MatriDerm® + split-thickness skin graft (with NPWT)	none	one-step	Natural and satisfaction
Duteille F.	2015	The Journal of Hand Surgery	MatriDerm [®] dermal substitute with split-thickness skin graft compared with full thickness skin graft for the coverage of skin defects after surgical treatments of congenital syndactyly: results in 40 commissures	retrospective, comparative	21	MatriDerm® + split-thickness skin graft (11 patients)	full-thickness skin graft (9 patients), 1 patient not reported	one-step	Matriderm surgical tin the full-thic was 0.8 (0
Kim Y.	2015	Journal of Korean Burn Society	A skin ulceration complicated by alcaligenes xylosoxidans infection	case report	1	MatriDerm® + split-thickness skin graft		one-step	Case repor resulting in traditional t skin graft v suggests th A. xylosoxid with MatriE
Özkan A.	2015	Journal of Cutaneous Medicine and Surgery	The use of the plasma blade and acellular dermal matrix in rhinophyma surgery: a case report	case report	1	MatriDerm® + split-thickness skin graft	none	one-step	Total excisi epidermal- rhinophym
Rha E.	2015	Arch Craniofac Surg (Archives of Craniofacial Surgery)	Surgical treatment of polyotia	case report	1	MatriDerm®	none	one-step	The article characteriz 3-year-old corrective redundant hollowness outcome.
Truffandier MV., Duteille F.	2015	Ann Chir Plast Esthet	Interest of dermal substitute (MatriDerm®) to cover long fingers after congenital syndactyly: About 20 commissures [article in French] (very similar to data published by Duteille 2015 in Journal of Hand Surgery)	case series	11	MatriDerm®	none	one-step	A retrospection syndactylie coverage. 2 44.6 mins. on the don gold stand
Meyer W.	2010	Plast Recons Surgery	Laminar implantation of a collagen-elastin matrix improves infraorbital contour in aesthetic facial surgery	prospective case series	29	MatriDerm® (2mm)		subdermally	64% show excellent re or foreign b
Ryssel H.	2010	Burns	MatriDerm [®] in-depth adjusted reconstruction of necrotizing fasciitis defects	case series	5	MatriDerm® + STSG		one-step	MatriDerm was indica vascular pr described weight bea
Selig H.	2013	International Journal of Surgery Case Reports	The surgical treatment of rhinophyma. Complete excision and single-step reconstruction by use of a collagen-elastin matrix and an autologous non-meshed split-thickness skin graft	case series	5	MatriDerm® + STSG		one-step	The article rhinophym MatriDerm reduced th outcomes. postoperat six-month satisfied w
Abed S.	2014	Annales de Dermatologie et de venereologie	The place of skin substitutes in surgical treatment of necrotizing cellulitis: Seven cases [French]	case series	7	MatriDerm® + STSG (1 patient) and Integra® (6 patients)		one-step (Integra® 2 step)	Excellent e second tim MatriDerm

mes/Summary

as renewed, regenerated in volume and texture and the patient to have a good healing of the skin color pigmentation and texture to the baseline. The scar tissue at the end of the treatment shows a net on both in texture and pigmentation with absence of retraction in the e. On examination, no pain was experienced upon palpation as well as se of adhesions and no restriction of movement in underlying tissues. No t was experienced with garments and no alteration in functionality

d pleasing outcome with no sexual impairment and high patient n. Decreased length of inpatient treatment duration, less scar formation.

[®] used for the treatment of congenital syndactyly. Reduction of ne by 10.5 min (19% reduction). OSAS score was equal to 11.9 (6-18) for ckness graft and to 12.1 (6-20) for the Matriderm[®] group. Withey's score 1-3) in the full-thickness graft and 1.2 (0-3) in the Matriderm[®] group.

rt of a healthy patient who developed an A. xylosoxidans infection n infectious skin ulceration with scar contracture that did not respond to treatments. The patient underwent a wide excision and split-thickness with MatriDerm[®] due to the incurable nature of the infection. The article hat scar contracture can compromise blood circulation leading to dans infection even in a healthy patient. The ulcer healed completely Derm[®].

ion of phymatous tissue and single session replacement of -dermal components is an effective treatment for patients with severe na, resulting in satisfactory functional and aesthetic outcome.

reports on a rare auricular malformation called polyotia, which is zed by a large accessory ear. The surgical correction of polyotia in a girl is presented, along with a review of the relevant literature. The surgery involved two stages, with the first stage addressing the skin, and the second stage using cartilage and MatriDerm[®] to fill in the s and reconstruct the neo-tragus. This led to a succesful clinical

ctive study was conducted on the surgical treatment of congenital es using MatriDerm[®] as a dermal substitute for lateral skin defects 20 commissures (11 children) were included and surgical time averaged The OSAS score for patients was 11.9, and there were no complications for site. The study suggests that MatriDerm[®] is a serious alternative to the lard technique of full-thickness skin graft for treating these skin defects.

ved good to excellent aesthetic results. 76% of patients reported good to esults. Dermal architecture (histology) showed no cellular inflammatory pody reaction at 6 months.

N® was used in patients with necrotizing fasciitis where normally a flap ted, but could not be realized due to patient refusal or insufficient reconditions. Take rate: 95%. Clinical course of 1 patient. with pictures of necrotizing fasciitis of lower extremity. Incl. exposed tendons. Full aring 12 days post-op.

describes a case report of a novel surgical approach for treating a, which involves deep excision, followed by the application of [®] and non-meshed split-thickness skin grafting. The use of this approach he risk of recurrence and provided satisfactory functional and aesthetic The study recruited five male patients and demonstrated no tive complications or hypertrophic scarring or recurrence within the follow-up period. Time to complete healing: 2 weeks. All patients were ith the results, and no surgical revisions were required.

elasticity and flexibility. Good recovery and functionality. No need for ne general anesthetic with MatriDerm®. Example of clinical case with ® and exposed tendon.

Miscellaneous

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Park	2016	Arch Craniofac Surg	Immediate Near-Total Scalp Reconstruction with Artificial Dermis on Exposed Calvarium	case report	1	MatriDerm [®] and meshed STSG		one-step	In a 78-year of a large so following wie complicatio
Schmidt	2017 a	Journal of Tissue Engineering and Regenerative Madicine	Hemodynamically stimulated and in vivo generated axially vascularized soft tissue free flaps for closure of complex defects: Evaluation in a small animal model	Animal Study/ prospektiv	35 female Sprague Dawley rats	group 2: AV loop flap produced by the use of MatriDerm® (2mm) + split thickness skin graft	group3: MatriDerm® (2mm) + split thickness skin graft group 1: split thickness skin graft	one-step	The article r the reconst found that t homogeneo sis was evid and mean v the matrix v generated f coverage co neovascular flaps.
Wollina U.	2017 a	Maced J Med Sci	Very Rare Amelanotic Lentigo Maligna Melanoma with Skull Roof Invasion	case report	1	MatriDerm® + meshed skin graft		one-step	In a 73-year skin coloure defect was graft. Healin the skin tran closed by sa
Niedermueller	2018	Unfallchirug	Necrotizing fasciitis of the hand and forearm. Acute surgical treatment and defect reconstruction with MatriDerm® and STSG	case report	1	MatriDerm® + STSG MatriDerm® wrapped around tendon		one-step	Apart from after coverin the skin clos patient alrea possible, the cosmetical
Jeong Hyun Ha	2019	Head and neck	Tracheostomy scar management by repositioning platysma muscle and applying an acellular dermal substitute	prospective case series	n=17	MatriDerm [®]		one-step	The use of p manage tra efficient teo In addition t to 2.324 (p- to 0.324±0 from 1.706± 5.000±0 to improved fr was 33.3 (ra technique.
Riehle	2020	Der Unfallchirurg	Therapie einer nekrotisierenden Weichgewebeinfektion [article in German]	case report	1	MatriDerm®		one-step	A 60-year-o persistent c leg, leading used to cov
You	2020	Journal of cosmetic Dermatology	The use of MatriDerm [®] and skin graft for reconstruction of complex wounds	case control study	15	MatriDerm® + FTSG (n=5)	FTSG (N = 10)	one-step	The study e skin grafts (Matriderm® patient satis FTSGs were 80% in boti nasal shape FTSG is a re
Namgoong	2020	Plastic and Reconstructive Surgery	Potential of Tissue-Engineered and Artificial Dermis Grafts for Fingertip Reconstruction	Observational Cohort Study	182	Tissue-engineered dermis grafts, MatriDerm®, Reverse digital artery island flaps	Not specified	No STSG	The study s fingertip del complete e
Coulie	2021	JPRAS Open	The use of MatriDerm [®] as a single salvage procedure to cover exposed dura mater	case report	1	MatriDerm® (1mm) + STSG	none	one-step	Case report mater after VAC dressir

omes/Summary

r-old woman, successfull perfomance of a single-stage reconstruction calp defect using a combination of MatriDerm®, split-thickness skin graft de excision of a cutaneous angiosarcoma. No wound infection or other ns reported up to 13 month postoperatively.

reports on a study that evaluated the use of AV-loop-generated flaps for ruction of critical bone-exposing defects using a rat model. The study the AV-loop-generated flaps resulted in stable wound coverage with ous vascular integration compared to the control groups. Neoangiogenedent in all constructs, and significant increases in mean vessel number vessel area were observed over time. Cell migration and proliferation into were also observed, with a significant increase over time. The AV-loop-'laps resulted in sufficient defect reconstruction and stable tissue ompared to the control groups. MatriDerm[®] efficiently promotes rization and is suitable for tissue engineering of vascularized soft tissue

r-old male patient LMM was removed by slow Mohs. 1 year later, another ed nodule of the bald head was removed by slow mohs surgery. The closed by sandwich transplantation with MatriDerm® and meshed skin ng was uneventful. Again 1 year later, a firm tumour proliferation around nsplant occures (LMM). Wide excision of the tumor. Defect was again andwich transplantation.

one area above the tendon graft, the soft tissues healed within 2 weeks ng. Only after removal of the avital graft – 8 weeks after reconstruction – ses completely. Approximately 4 months after reconstruction, the ady has sensitive areas on half of the skin graft, the pincer grip is weakly e skin sufficiently elastic for wrist and finger movements and by appealing. The patient achieves a DASH score of 50.8.

platysma muscle repositioning and an acellular dermal substitute to tacheostomy scars in 17 patients was found to be a simple and shnique, which improved the appearance and function of the scar. to the mean total Vancouver Scar Scale score improving from 8.265 < 0.0001), the mean pigmentation score improved from 1.412 \pm 0.690 0.431 after surgery (P<0.0001). The vascularity score also improved t1.091 to 0.500 \pm 0.395 (P = 0.001). The pliability score improved from 0.706 \pm 0.254 (P<0.0001), and the mean height (depression) score om 1.47 \pm 0.294 to 0.765 \pm 0.359 (P<0.0001). The follow-up period ange, 12v-60) months, indicating the long-term effectiveness of the

old man presented at the emergency department with fever and cough. He had a joint infection and abscess formation in his left lower to sepsis. Surgical intervention was necessary, and MatriDerm[®] was rer a resulting wound. He regained normal physical activity within a year.

evaluated the outcomes of combining Matriderm® with full-thickness (FTSG) for nasal skin defect closure in five patients. The use of Presulted in statistically superior scar quality (8.0 ±1.9) and higher sfaction compared to conventional FTSG. One-stage Matriderm®-aided e well-taken in all cases, and the overall survival rate of the FTSG was h groups. Matriderm® also provided superior graft shine and alleviated e distortion. The study concludes that Matriderm® in combination with eliable method for covering nasal skin defects.

suggests that MatriDerm® may be a promising alternative for managing fects and lead to lowering the costs. It can induce fine granulation, and pithelialization can be achieved without secondary skin grafting.

t of a 79-year old women with a large cranial defect and exposed dura free flap failure. One stage application of MatriDerm[®] and STSG with a ng resulted in stable calvarian reconstruction at 3 months.

Miscellaneous

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Sanz del Pozo (Monclus)	2021	European Journal of Plastic Surgery	The use of Matriderm [®] for penile reconstruction: a case series	case series	4	MatriDerm® (1mm) + STSG			Four patien of injury var and surgica aesthetic ou highlights th recommend
Dhannoon	2022	JPRAS Open	Acellular dermal substitute use in reconstruction of axillary hydradenitis suppurativa	case report	1	MatriDerm® (1mm)	none	one-step	A 33-year-o an immedia shoulder m life. Matride
Lee	2023	Annals of Plastic Surgery	Management of Hardware-Exposed soft Tissue Defects Using Dermal Substitutes and Negative Pressure Wound Therapy	retrospective case series	14	MatriDerm®		one-step	14 patients treated with MatriDerm [®] duration of injury type, more replac changes wf grafting with NPWT and wounds, wf

Mucosa

First Author	Year	Journal	Title	Study Type	Number of patients	Treatment group	Control group	One-Step procedure?	Main Outco
Pauchot	2016	Annales de chirurgie plastique esthétique	Conformation du lambeau antébrachial en arche sur mesure pour la reconstruction du voile du palais. Cas clinique	case report	1			one-step	MatriDerm [®] flap design
Cella	2018	Chirurgia	Surgical oral defects: proposal for a new solution	case serie	40	MatriDerm [®]			A clinical str treated had shorter hea MatriDerm [®] results, and
Alonso	2019	International Journal of Pediatric Otorhinolaryngology	Three-layered repair with a collagen membrane and a mucosal rotational flap reinforced with fibrine for palatal fistula closure in children	case report	1	MatriDerm [®]			Three layers mucosa, an The methoo complicatio should inclu speech, lan
Singh	2023	J Cleft Lip Palate Craniofac Anomal	Dermal substitute reinforced single-layer closure of the palatal fistula	case report	1			two-step	A 3.5-year- fistulous sc but not the over the na almost com leaked into

omes/Summary

nts with penile wounds were treated using MatriDerm[®]. The mechanism uried, including subcutaneous penile paraffin injection, electrical burn, al complication. The use of MatriDerm[®] resulted in a good functional and butcome, with no cases of total or partial loss reported. The study the importance of using dermal matrices in penile wounds and nds multidisciplinary collaboration for better management and results.

-old female with refractory HS was reconstructed with Matriderm[®] and ate split-thickness skin graft. The patient demonstrated no restriction in novement and reported improved pain, self-esteem, and overall quality of erm[®] may be a durable and effective alternative for HS reconstruction.

with hardware-exposing wounds after internal fixation using plates were h the wound management procedure, involving surgical debridement, [®] placement, and negative pressure wound therapy (NPWT). The treatment and number of NPWT replacements were stratified based on with open fractures requiring significantly longer NPWT and undergoing cements. Patients with open fractures underwent a mean of 6.6 NPWT hile those with closed fractures underwent 2.5 (P=0.002). However, skin h MatriDerm[®] was successful in all 14 patients. The study reveals that MatriDerm[®]-augmented skin grafting are useful for hardware-exposed here flap surgery has been considered the only treatment.

omes/Summary

Is used to cover the doner site (60-year-old male) of a "double-arched" of reconstructing soft palate defects after oncologic resection.

tudy on the use of MatriDerm[®] in oral surgery showed that all 40 patients d complete restitution as integrum, with no bleeding phenomena and a aling time compared to traditional surgery. The study suggests that [®] can be a good approach to reducing healing time, improving final d avoiding the risk of recurrences in oral surgery.

red repair, with a MatriDerm[®] placed over the reconstructed nasal nd a rotational palatal mucosa flap reinforced with a fibrine sealant. In the sealant sealant is simple, easy to reproduce, effective and has a low rate of ons. The multidisciplinary treatment of the child with a cleft lip and palate lude the repair of the birth defect (lip, palate, and nose), achieving normal nguage, hearing, functional occlusion, and good dental health.

-old boy presented with anterior palatal fistula. The presence of pericarring prevented two-layered closure. Nasal layer closure was achieved e oral layer. The dermal matrix was reinforced in a one-step procedure asal layer and fixed in place using a gel foam. At 6 months, the fistula mpletely healed, with only a pinpoint track remaining that occasionally o the nasal cavity.

MatriDerm[®] Flex Dermal Matrix

	Ref. No.	Size
	83440 - 200	210 x 297 x 1mm
A4	83460 - 200	210 x 297 x 2mm
	83470 - 200	210 x 297 x 3mm
	83441 - 200	105 x 148 x 1mm
A6	83461 - 200	105 x 148 x 2mm
	83471 - 200	105 x 148 x 3 mm
	83442 - 200	52 x 74 x 1mm
A8	83462 - 200	52 x 74 x 2mm
	83472 - 200	52 x 74 x 3mm
	83443 - 200	37 x 52 x 1mm
A9	83463 - 200	37 x 52 x 2mm
	83473 - 200	37 x 52 x 3mm

MatriDerm[®]Fenestrated Dermal Matrix

	Ref. No.	Size
	83410 - 200	210 x 297 x 1mm
A4	83420 - 200	210 x 297 x 2mm
	83430 - 200	210 x 297 x 3 mm
	83411 - 200	105 x 148 x 1mm
A6	83421 - 200	105 x 148 x 2mm
	83431 - 200	105 x 148 x 3mm
	83412 - 200	52 x 74 x 1mm
A8	83422 - 200	52 x 74 x 2mm
	83432 - 200	52 x 74 x 3mm
	83413 - 200	37 x 52 x 1mm
A9	83423 - 200	37 x 52 x 2mm
	83433 - 200	37 x 52 x 3mm

MatriDerm®Dermal Matrix

	Ref. No.	Size
	83500 - 200	210 x 297 x 1mm
A4	83400 - 200	210 x 297 x 2mm
4.0	83403 - 200	105 x 148 x 1mm
A6	83401 - 200	105 x 148 x 2mm
A8	83404 - 200	52 x 74 x 1mm
A9	83405 - 200	37 x 52 x 1mm

A4 210 x 297 mm





Please check complete indications and recommended application in your local Instructions for Use (IFU) before using MatriDerm®Dermal Matrix.



MedSkin Solutions Dr. Suwelack AG, Josef-Suwelack-Strasse 2, 48727 Billerbeck, Germany +49 (0) 2543 2182-0 info@medskin-suwelack.com MatriDerm®.com

Material number 89629-004

UK DISTRIBUTOR

